ocera  hope for patients promise for families hope for patients promise for families critical drug discoveries for unmet medical needs pioneering lifechanging medicines hope for patients promise for families critical drug discoveries for unmet medical needs pioneering lifechanging medicines our mission ocera therapeutics is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with serious liver diseases in areas of high unmet medical need download fact sheet about he hepatic encephalopathy he is a debilitating and progressive complication of liver cirrhosis or liver failure marked by mental changes including confusion impaired motor skills disorientation and in its more severe form stupor coma and even death see more recent news ocera initiates phase a study with oral ocr in patients with cirrhosisthursday june  ocera therapeutics to host kol conference call on hepatic encephalopathy and other complications of liver disease on friday june friday may   see more investor relations  ocera innovation integrity impact nasdaq ocrx    day high  day low   volume      pm et jul   delayed  min by esignal  mo  mo  yr shareholder tools briefcase printed materials email alerts downloads snapshot email share rss facebook google linkedin twitter email rss investor relations ocera therapeutics nasdaqocrx is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with serious diseases in areas of high unmet medical need news jun   ocera initiates phase a study with oral ocr in patients with cirrhosis may   ocera therapeutics to host kol conference call on hepatic encephalopathy and other complications of liver disease on friday june  view all news » presentations  events jun   at  am et ocera kol conference call on unmet needs in hepatic encephalopathy and other complications of liver disease may   at  pm et q  financial results and clinical update view all presentations  events » news  ocera nasdaq ocrx    day high  day low   volume      pm et jul   delayed  min by esignal  mo  mo  yr shareholder tools briefcase printed materials email alerts downloads snapshot email share rss facebook google linkedin twitter email rss news view all categories news releases conference presentations earnings announcements financial results year all years      sort by date descending date ascending update   news   date title view jun   ocera initiates phase a study with oral ocr in patients with cirrhosis redwood city calif and research triangle park nc june   globe newswire  ocera therapeutics inc nasdaqocrx today announced the dosing of the first patients in part two of a phasephase a clinical trial of oral ocr ornithine phenylacetate oral ocr is a validated ammonia scavenger in development for use as a  pdf add to briefcase file is in briefcase may   ocera therapeutics to host kol conference call on hepatic encephalopathy and other complications of liver disease on friday june  redwood city calif and research triangle park nc may   globe newswire  ocera therapeutics inc nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic liver diseases today announced that it will host a key opinion leader call on the topic of hepatic encephalopathy and other comp pdf add to briefcase file is in briefcase may   ocera therapeutics reports first quarter  financial results and provides clinical update posthoc per protocol analysis demonstrates ocr achieved primary endpoint with statistical significance p company to host conference call and webcast today at  pm et redwood city calif and research triangle park nc may   globe newswire  ocera th pdf add to briefcase file is in briefcase may   ocera therapeutics to report first quarter  financial results and provide clinical update on may   redwood city calif and research triangle park nc may   globe newswire  ocera therapeutics inc nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced that it will report its first quarter  financial results and provide a clinical upd pdf add to briefcase file is in briefcase apr   ocera therapeutics announces presentation of data showing ocr prevented progression of fibrosis in preclinical model of nonalcoholic fatty liver disease nafld supports potential for ocr in the treatment of nafldnash data to be presented at the international liver congress™  of the european association for the study of the liver easl palo alto calif and research triangle park nc april    pdf add to briefcase file is in briefcase mar   ocera to present at the th annual needham healthcare conference palo alto calif and research triangle park nc march   globe newswire  ocera therapeutics inc nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced that michael byrnes chief financial officer will be presenting at the upcoming th annual n pdf add to briefcase file is in briefcase mar   ocera therapeutics reports fourth quarter and full year  financial results and provides corporate update palo alto calif and research triangle park nc march   globe newswire  ocera therapeutics inc nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced updates to its clinical development programs and reported financial results for the quarter and year ende pdf add to briefcase file is in briefcase mar   ocera to announce additional encouraging results from its phase b stophe study of iv ocr in patients with hepatic encephalopathy iv ocr statistically significantly normalized ammonia faster than standard of care ammonia reduction statistically significantly correlated with clinical improvement in he symptoms ocera plans to meet with fda in q  to inform development paths forward f pdf add to briefcase file is in briefcase feb   ocera to present at the cowen and company th annual healthcare conference palo alto calif and research triangle park nc feb   globe newswire  ocera therapeutics inc nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced that linda grais md chief executive officer will be presenting at the upcoming cowen and company  pdf add to briefcase file is in briefcase jan   ocera announces topline results for phase b study in hepatic encephalopathy primary and secondary endpoints showed trend and doserelated clinical benefit although not statistically significant ammonia scavenger ocr demonstrated statistically significant reduction in ammonia levels ocr pdf add to briefcase file is in briefcase jan   ocera announces successful phase  clinical study of orallyadministered ocr in patients with cirrhosis data support feasibility of oral ocr as maintenance therapy for patients with hepatic encephalopathy company plans to initiate phase a in h  with new optimized tablet formulation palo alto calif and research triangle park nc jan   globe newswire  oce pdf add to briefcase file is in briefcase dec   ocera completes enrollment of stophe a phase b study of ocr in hospitalized patients with hepatic encephalopathy palo alto calif and research triangle park nc dec   globe newswire  ocera therapeutics inc nasdaqocrx today announced it has completed enrollment in its phase b stophe study evaluating the efficacy safety and tolerability of ornithine phenylacetate ocr in hos pdf add to briefcase file is in briefcase nov   ocera to present at the stifel  healthcare conference palo alto calif and research triangle park nc nov   globe newswire  ocera therapeutics inc nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced that linda grais md chief executive officer will be presenting at the upcoming stifel  healthcare pdf add to briefcase file is in briefcase nov   ocera therapeutics reports third quarter  financial results and company update palo alto calif and research triangle park nc nov   globe newswire  ocera therapeutics inc nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today reported financial results for the quarter ended september   and provided updates on its clinical developmen pdf add to briefcase file is in briefcase oct   ocera therapeutics appoints biopharmaceutical veteran willard dere md to board of directors palo alto calif and research triangle park nc oct   globe newswire  ocera therapeutics inc nasdaqocrx today announced that willard dere md professor of internal medicine at the university of utah health sciences center and former senior vice president in research and development at amgen has been appointed to the pdf add to briefcase file is in briefcase oct   ocera therapeutics announces latebreaker abstract accepted for presentation at the aasld liver meeting  palo alto calif and research triangle park nc oct   globe newswire  ocera therapeutics inc nasdaqocrx today announced that clinical data from stopalf a phase a clinical trial to evaluate the safety and tolerability of ornithine phenylacetate ocr pdf add to briefcase file is in briefcase oct   ocera to present at the  bio investor forum palo alto calif and research triangle park nc oct   globe newswire  ocera therapeutics inc nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced that linda grais md chief executive officer will be presenting at the upcoming  bio investor foru pdf add to briefcase file is in briefcase sep   ocera announces enrollment completion from phase a nihsponsored study of ocr in the treatment of patients with acute liver failure palo alto calif and research triangle park nc sept   globe newswire  ocera therapeutics inc nasdaqocrx today announced completion of enrollment in stopalf  a phase a clinical trial to evaluate the safety and tolerability of ornithine phenylace pdf add to briefcase file is in briefcase sep   ocera to present at the ladenburg thalmann nd annual healthcare conference palo alto calif and research triangle park nc sept   globe newswire  ocera therapeutics inc nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced that linda grais md chief executive officer will be presenting at the ladenburg thalmann nd pdf add to briefcase file is in briefcase sep   ocera initiates phase  clinical study of orally available ocr in patients with cirrhosis for the prevention of hepatic encephalopathy phase b stophe enrollment surpasses  patients on track to complete in q  palo alto calif and research triangle park nc sept   globe newswire  ocera therapeutics inc nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic o pdf add to briefcase file is in briefcase sep   ocera announces management transition palo alto calif and research triangle park nc sept   globe newswire  ocera therapeutics inc nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced a transition in the business development team at ocera gaurav aggarwal md chief business officer of  pdf add to briefcase file is in briefcase aug   ocera therapeutics reports second quarter  financial results and company update palo alto calif and research triangle park nc aug   globe newswire  ocera therapeutics inc nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today reported financial results for the quarter ended june   and provided updates on its clinical development pro pdf add to briefcase file is in briefcase jun   ocera to present at the jmp securities life sciences conference palo alto calif and research triangle park nc june   globe newswire  ocera therapeutics inc nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced that linda grais md chief executive officer will be presenting at the jmp securities lif pdf add to briefcase file is in briefcase may   ocera to present at the jefferies  healthcare conference palo alto calif and research triangle park nc may   globe newswire  ocera therapeutics inc nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced that linda grais md chief executive officer will be presenting at the jefferies  healthcare confer pdf add to briefcase file is in briefcase may   ocera to present at the  bio international convention palo alto calif and research triangle park nc may   globe newswire  ocera therapeutics inc nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced that gaurav aggarwal md chief business officer will be presenting at the  bio international conven pdf add to briefcase file is in briefcase apr   ocera therapeutics reports first quarter  financial results and pipeline progress  company on target to complete enrollment in stophe in the fourth quarter approximately  patients enrolled to date   study with orallyavailable ocr in patients with cirrhosis to begin in the third quarter with data expected by yearend  palo alto calif an pdf add to briefcase file is in briefcase apr   ocera therapeutics announces presentation of two preclinical studies further supporting its ammonia scavenger ocr at the international liver congress™  of the european association for the study of the liver easl data establish ammonialowering properties of orallyadministered ocr in preclinical model of cirrhosisdata highlight cns neurochemical changes occurring in preclinical model of hepatic encephalopathy which are normalized with ocr palo alto calif and pdf add to briefcase file is in briefcase apr   ocera therapeutics announces publication of promising preclinical data in support of its ammonia scavenger ocr in the journal of hepatology palo alto calif and research triangle park nc april   globe newswire  ocera therapeutics inc nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced the publication of promising preclinical data related to the companys investigational drug candidate orn pdf add to briefcase file is in briefcase apr   ocera to present at the th annual needham healthcare conference palo alto calif and research triangle park nc april   globe newswire  ocera therapeutics inc nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced that linda grais md chief executive officer will be presenting at the th annual needham pdf add to briefcase file is in briefcase mar   ocera therapeutics reports fourth quarter and full year  financial results and provides corporate update  patient enrollment progressing in stophe clinical trial of ocr company expects to complete enrollment in the fourth quarter of    ocr is the only ammonia scavenger in development for both treatment and prevention of hepatic encephalopathy he  palo alto ca pdf add to briefcase file is in briefcase feb   ocera to present at the cowen and company th annual health care conference palo alto calif and research triangle park nc feb   globe newswire  ocera therapeutics inc nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced that linda grais md chief executive officer will be presenting at the cowen and company th pdf add to briefcase file is in briefcase feb   ocera to present at the th annual bio ceo  investor conference palo alto calif and research triangle park nc feb   globe newswire  ocera therapeutics inc nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced that the company will be presenting at the th annual bio ceo  investor conference taking pla pdf add to briefcase file is in briefcase jan   ocera announces complete plasma data from pilot phase  study for orallyavailable ocr in development for the prevention of chronic hepatic encephalopathy palo alto calif and research triangle park nc jan   globe newswire  ocera therapeutics inc nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced further details from its phase  study of oral formulations of ocr ornithine phenylacetate in health pdf add to briefcase file is in briefcase jan   ocera appoints dr stan bukofzer as chief medical officer palo alto calif and research triangle park nc jan   globe newswire  ocera therapeutics inc nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced the appointment of dr stan bukofzer as chief medical officer dr bukofzer most recently served as chief  pdf add to briefcase file is in briefcase nov   ocera announces positive phase  results for oral ocr in development for the prevention of chronic hepatic encephalopathy palo alto calif and research triangle park nc nov   globe newswire  ocera therapeutics inc nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced positive results from the companys phase  study of the oral formulation of ocr ornithine phenylacet pdf add to briefcase file is in briefcase nov   ocera to present at stifel  healthcare conference palo alto calif and research triangle park nc nov   globe newswire  ocera therapeutics inc nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced that gaurav aggarwal md chief business officer will be presenting at the stifel  healthcare confer pdf add to briefcase file is in briefcase nov   ocera therapeutics reports third quarter  financial results    stophe reaches  enrollment expected completion h   accepted abstracts at the liver meeting®  underscore the potential breadth of therapeutic application for ocr palo alto calif and research trian pdf add to briefcase file is in briefcase oct   ocera to present at bio investor forum  palo alto calif and research triangle park nc oct   globe newswire  ocera therapeutics inc nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced that linda grais md chief executive officer will be presenting at the  bio investor forum being h pdf add to briefcase file is in briefcase oct   ocera therapeutics highlights ocr data to be presented at the annual meeting of the american association for the study of liver diseases aasld palo alto calif and research triangle park nc oct   globe newswire  ocera therapeutics inc nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced that  abstracts involving the companys drug candidate ocr ornithine phenylacetat pdf add to briefcase file is in briefcase sep   ocera initiates phase  clinical trial of oral drug candidate ocr for prevention of hepatic encephalopathy palo alto calif and research triangle park nc sept   globe newswire  ocera therapeutics inc nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced that the company has initiated a phase  clinical trial in healthy subjects to evaluate the pharmacokineti pdf add to briefcase file is in briefcase sep   ocera to present at the rodman  renshaw th annual global investment conference palo alto calif and research triangle park nc sept   globe newswire  ocera therapeutics inc nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced that linda grais md chief executive officer will be presenting at the rodman  renshaw th pdf add to briefcase file is in briefcase aug   ocera therapeutics reports second quarter  financial results continued strong enrollment in stophe on track for initiation of phase  trial with oral formulation of ocr in third quarter  million debt facility extends cash resources to mid palo alto calif and research triangle park nc  pdf add to briefcase file is in briefcase jul   ocera therapeutics secures  million debt facility from oxford finance and silicon valley bank pdf add to briefcase file is in briefcase jun   ocera therapeutics to present at the jmp securities life sciences conference palo alto calif june   globe newswire  ocera therapeutics inc nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced that gaurav aggarwal md chief business officer will be presenting at the jmp securities life sciences conference being held at the st pdf add to briefcase file is in briefcase may   ocera therapeutics to present at the jefferies  healthcare conference palo alto calif may   globe newswire  ocera therapeutics inc nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced that linda grais md chief executive officer will be presenting at the jefferies  healthcare conference being held at the grand hyatt in ne pdf add to briefcase file is in briefcase may   ocera ceo to be honored at the th annual american liver foundations salute to excellence awards gala in san francisco palo alto calif may   globe newswire  ocera therapeutics inc nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced that linda grais md chief executive officer is an honoree at this years american liver foundations salute to excellence awards gala to be hel pdf add to briefcase file is in briefcase may   ocera therapeutics announces change in executive team palo alto calif may   globe newswire  ocera therapeutics inc nasdaqocrx today announced that rajiv patni md chief development officer has decided to step down from his position for personal reasons effective june   the companys former chief development and chief medical officer franck rousseau md who has been a pdf add to briefcase file is in briefcase apr   ocera reports pipeline progress and first quarter  financial results strong enrollment in stophe trialconference call and webcast at  am et palo alto calif april   globe newswire  ocera therapeutics inc nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today provided updates on its clinical development programs of ocr for the pdf add to briefcase file is in briefcase apr   ocera therapeutics to report pipeline progress and first quarter  financial results palo alto calif april   globe newswire  ocera therapeutics inc nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced that it will release its first quarter  financial results on thursday april   at approximately  am eastern time in conjunction pdf add to briefcase file is in briefcase apr   ocera completes interim analysis of ocr in phase b stophe study for the treatment of acute hepatic encephalopathy palo alto calif april   globe newswire  ocera therapeutics inc nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced successful completion of a planned interim analysis of its stophe study a doubleblind placebocontrolled study of ocr in patients with acut pdf add to briefcase file is in briefcase mar   ocera reports fourth quarter and full year  financial results palo alto calif march   globe newswire  ocera therapeutics inc nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced updates to its clinical development programs and reported financial results and other business highlights for the quarter and year ended december pdf add to briefcase file is in briefcase mar   ocera therapeutics to announce fourth quarter and full year  financial results palo alto calif march   globe newswire  ocera therapeutics inc nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced that it will release its fourth quarter and full year  financial results and other information on wednesday march   at approximately  pdf add to briefcase file is in briefcase feb   ocera therapeutics to present at th annual cowen and company health care conference palo alto calif feb   globe newswire  ocera therapeutics inc nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced that company management will be presenting at the th annual cowen and company health care conference being held at the boston marriott copley pl pdf add to briefcase file is in briefcase feb   ocera announces preliminary topline results from phase a investigatorsponsored study of ocr palo alto calif feb   globe newswire  ocera therapeutics inc nasdaqocrx today announced preliminary topline results from a phase a investigatorsponsored study evaluating the companys drug candidate ocr ornithine phenylacetate versus placebo in patients with upper gastrointestinal bleeding ugib associated with liver ci pdf add to briefcase file is in briefcase dec   ocera therapeutics promotes michael byrnes to chief financial officer palo alto calif dec   globe newswire  ocera therapeutics inc nasdaqocrx a clinicalstage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced the appointment of michael byrnes as chief financial officer michaels exemplary combination of business acumen professionalism and integrit pdf add to briefcase file is in briefcase nov   ocera reports third quarter  financial results palo alto calif nov   globe newswire  ocera therapeutics inc nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced recent business highlights and reported financial results for the quarter ended september   in the third quarter ocera made meaningf pdf add to briefcase file is in briefcase nov   ocera therapeutics to present at stifel  healthcare conference palo alto calif nov   globe newswire  ocera therapeutics inc nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced that company management will be presenting at the stifel  healthcare conference being held at the palace hotel in new york ny oceras presen pdf add to briefcase file is in briefcase nov   ocera therapeutics to announce third quarter  financial results palo alto ca  november    ocera therapeutics inc nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced that it will release its third quarter  financial results on thursday november   at approximately  pm eastern time in conjunction with  pdf add to briefcase file is in briefcase sep   ocera therapeutics to present at th annual bio investor forum palo alto calif sept   globe newswire  ocera therapeutics inc nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced that company management will be presenting at the th annual bio investor forum being held at the palace hotel in san francisco california oce pdf add to briefcase file is in briefcase sep   ocera therapeutics announces appointment of steven p james to board palo alto calif sept   globe newswire  ocera therapeutics inc nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced that steven p james has been appointed to the companys board of directors mr james will serve as the lead independent director and will be th pdf add to briefcase file is in briefcase aug   ocera announces appointment of rajiv patni md as chief development officer palo alto calif aug   globe newswire  ocera therapeutics inc nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced that rajiv patni md has been appointed as the companys chief development officer dr patni will commence his employment with ocera on septemb pdf add to briefcase file is in briefcase aug   ocera reports second quarter  financial results palo alto calif aug   globe newswire  ocera therapeutics inc nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced its financial results for the second quarter ended june   net loss for the period was  million compared to a net loss of  million pdf add to briefcase file is in briefcase jul   ocera therapeutics to announce second quarter financial results palo alto calif july   globe newswire  ocera therapeutics nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced that it will release its second quarter financial results on august   at approximately  pm eastern time the company will host a conference pdf add to briefcase file is in briefcase jul   ocera therapeutics raises  million in public offering palo alto calif july   globe newswire  ocera therapeutics nasdaqocrx ocera today announced that it has priced an underwritten public offering of  shares of its common stock at an offering price of  per share the offering will raise gross proceeds to ocera of  million before deducting the underwriting discoun pdf add to briefcase file is in briefcase jul   ocera therapeutics announces proposed public offering of common stock palo alto calif july   globe newswire  ocera therapeutics nasdaqocrx ocera or the company today announced that it intends to offer and sell subject to market and other conditions shares of its common stock in an underwritten public offering stifel and cowen and company are acting as joint bookrunning managers for the of pdf add to briefcase file is in briefcase jun   ocera therapeutics to present at the jmp securities healthcare conference  palo alto calif june   globe newswire  ocera therapeutics nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases announced today that company management plans to present at the jmp securities healthcare conference  oceras presentation is scheduled for wednesday june   pdf add to briefcase file is in briefcase may   ocera therapeutics to present at the jefferies  global healthcare conference palo alto calif may   globe newswire  ocera therapeutics nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases announced today that company management plans to present at the jefferies  global healthcare conference oceras presentation is scheduled for thursday june   pdf add to briefcase file is in briefcase may   ocera reports first quarter financial results palo alto calif may   globe newswire  ocera therapeutics inc nasdaqocrx a biopharmaceutical company focused on innovative therapeutics for orphan liver disease announced today its financial results for the first quarter ended march   net loss for the period was  million including net loss from continuing operations  pdf add to briefcase file is in briefcase may   ocera therapeutics announces appointment of gaurav aggarwal md as chief business officer palo alto calif may   globe newswire  ocera therapeutics nasdaqocrx today announced that gaurav aggarwal md has joined the company as its chief business officer we are excited that gaurav is joining ocera to help shape our future partnering and other strategic initiatives said linda grais md chief executive officer o pdf add to briefcase file is in briefcase apr   ocera therapeutics to announce first quarter financial results palo alto calif april   globe newswire  ocera therapeutics nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced that it will release its first quarter financial results on may   at approximately  pm eastern time the company will host a conference cal pdf add to briefcase file is in briefcase mar   ocera reports fourth quarter and yearend  financial results palo alto calif march   globe newswire  ocera therapeutics inc nasdaqocrx a biopharmaceutical company focused on innovative therapeutics for orphan liver disease announced today its financial results and other information for the fourth quarter and year ended december   revenues from continuing operations for the fourth pdf add to briefcase file is in briefcase mar   ocera therapeutics to announce fourth quarter and year end financial results palo alto calif march   globe newswire  ocera therapeutics nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced that it will release its fourth quarter financial results on march   at approximately  pm eastern time the company will host a conference  pdf add to briefcase file is in briefcase feb   ocera therapeutics to present at the cowen and company th annual health care conference palo alto calif feb   globe newswire  ocera therapeutics nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases announced today that company management plans to present at the cowen health care conference oceras presentation is scheduled for wednesday march   at  am  pdf add to briefcase file is in briefcase jan   ocera therapeutics announces enrollment of the first patient in a phase iib study for treatment of acute hepatic encephalopathy palo alto calif jan   globe newswire  ocera therapeutics nasdaqocrx today announced enrollment of the first patient in its multicenter phase b study the stophe or ocrhe trial this study is evaluating the efficacy safety and pharmacokinetics of ocr or ornithine phenylacetate in hospitalized patients with liver c pdf add to briefcase file is in briefcase dec   ocera therapeutics announces election of wendell wierenga to board palo alto calif dec   globe newswire  ocera therapeutics nasdaqocrx today announced that wendell wierenga phd has joined its board of directors we are excited that wendell has accepted our offer to join our board and we will benefit greatly from his leadership as we advance our phase b clinical trials said linda grai pdf add to briefcase file is in briefcase dec   ocera therapeutics and the roche group enter into technology transfer and license agreement palo alto calif dec   globe newswire  ocera therapeutics nasdaqocrx today announced that it has entered into a technology transfer and license agreement with the roche group including the research and early development arms of both genentech and roche for rights to its macrocyclic template chemistry match™ discovery plat pdf add to briefcase file is in briefcase dec   ocera therapeutics announces staffing transition palo alto calif dec   globe newswire  ocera therapeutics nasdaqocrx today announced that david s moore its chief business officer will be leaving ocera to pursue other opportunities mr moore was a former member of the management team at tranzyme and continued his employment with ocera following the merger of ocera and tranzym pdf add to briefcase file is in briefcase nov   ocera therapeutics to present at piper jaffrey healthcare conference palo alto calif nov   globe newswire  ocera therapeutics nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced that linda grais md president and chief executive officer plans to present at the th annual piper jaffrey healthcare conference taking place at t pdf add to briefcase file is in briefcase nov   ocera reports third quarter business update and financial results palo alto calif nov   globe newswire  ocera therapeutics inc nasdaqocrx a biopharmaceutical company focused on innovative therapeutics for orphan liver disease announced today financial results for the three and nine months ended september  ocera business updates since the start of the third quarter oceras busine pdf add to briefcase file is in briefcase nov   ocera therapeutics announces  million private placement san diego nov   globe newswire  ocera therapeutics inc nasdaqocrx a biopharmaceutical company focused on innovative therapeutics for orphan liver disease announced today that it has obtained commitments to purchase common stock and warrants in a private placement gross proceeds from the private placement are expected to be  m pdf add to briefcase file is in briefcase sep   ocera therapeutics to present at bio investor on october   san diego sept   globe newswire  ocera therapeutics nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced that linda grais md president and chief executive officer will present at the th annual bio investor forum taking place at the palace hotel in san franc pdf add to briefcase file is in briefcase sep   ocera announces postmerger closure of quebec research site san diego sept   globe newswire  ocera therapeutics nasdaqocrx a clinical stage biopharmaceutical company focusing on acute and chronic orphan liver diseases today announced a restructuring plan involving the closure of operations in its sherbrooke quebec facility effective november   the sherbrooke facility housed  emp pdf add to briefcase file is in briefcase sep   jeryl l hilleman joins ocera therapeutics as chief financial officer san diego sept   globe newswire  ocera therapeutics nasdaqocrx a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced that jeryl l hilleman has been appointed chief financial officer effective september   ms hilleman will replace dana mcgowan who will continue with the pdf add to briefcase file is in briefcase aug   ocera therapeutics announces second quarter  financial results san diego aug   globe newswire  ocera therapeutics inc ocera or the company nasdaqocrx a clinical stage biopharmaceutical company focused on the development and commercialization of proprietary compounds to treat acute and chronic orphan liver diseases today announced its financial results and business update for the secon pdf add to briefcase file is in briefcase jul   ocera therapeutics to report second quarter  financial results san diego july   globe newswire  ocera therapeutics nasdaqocrx today announced that the company will report second quarter  financial results after the close of the market on tuesday august  about ocera therapeutics ocera therapeutics inc based in san diego california with an office in research triangle park nor pdf add to briefcase file is in briefcase jul   ocera therapeutics announces completion of merger with tranzyme san diego july   globe newswire  ocera therapeutics inc ocera a clinical stage biopharmaceutical company developing novel therapeutics for orphan liver diseases and tranzyme inc nasdaqtzym tranzyme today announced that following a special meeting of the shareholders of tranzyme held on july   the ocera and tran pdf add to briefcase file is in briefcase  add release to briefcase ocera  company focused on rare diseases and their ripple effects ocr has been granted orphan drug designation and fast track status by the fda for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acuteonchronic liver disease overview ocera therapeutics nasdaqocrx is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for orphan and other serious growing liver diseases with high unmet medical need ocera’s lead drug prorgam is ocr a novel and validated ammonia scavenger which rapidly removes ammonia from the blood elevated ammonia is believed to be one of the primary causes of hepatic encephalopathy he a neurocognitive disorder associated with serious liver disease an intravenouslyadministered form of ocr was the subject of a recently completed phase b trial stophe in patients hospitalized with he and an oral form of the study drug is being evaluated in an ongoing phase a trial in patients with cirrhosis ocr has received orphan drug designation and has been granted fast track status by the us food and drug administration see ocr for additional information products to treat acute and chronic orphan and other serious growing liver diseases ocera’s drug candidate ocr ornithine phenylacetate is a validated ammonia scavenger designed to treat hyperammonemia elevated ammonia in the blood and associated hepatic encephalopathy a complication of patients with liver cirrhosis or acute liver failure when the liver is no longer able to remove toxic substances from the blood there is an accumulation of such toxins particularly ammonia ammonia accumulation in the blood impairs brain cell function and can lead to a neuropsychiatric condition called hepatic encephalopathy or he management team linda s grais md president and chief executive officer dr grais has served as a member of the board of directors and as our president and chief executive officer since the date of the merger with tranzyme inc in july  the “merger” as a member of the board of directors of ocera therapeutics inc when it was a privately held delaware corporation “private ocera” since january  and as president and chief executive officer of private ocera since june  prior to her employment by private ocera dr grais served as a managing member at interwest partners a venture capital firm from may  until february  from july  to july  dr grais was a founder and executive vice president of sgx pharmaceuticals inc a drug discovery company focusing on new treatments for cancer prior to that she was a corporate attorney at wilson sonsini goodrich  rosati where she practiced in such areas as venture financings public offerings and strategic partnerships before practicing law dr grais worked as an assistant clinical professor of internal medicine and critical care at the university of california san francisco she currently serves on the board of directors of arca biopharma inc nasdaqabio and pra health sciences nasdaqprah dr grais received a ba from yale university magna cum laude and phi beta kappa an md from yale medical school and a jd from stanford law school stan bukofzer md chief medical officer dr bukofzer joined ocera therapeutics inc in january  prior to his employment with ocera he served as chief medical officer of hospira inc where he was responsible for providing strategic and operational direction for clinical development pharmacovigilance and safety and medical affairs across hospira’s three business units prior to joining hospira dr bukofzer was vice president of astellas scientific and medical affairs where he had responsibility for seven therapeutic areas including oncology immunology hematology antiinfectives dermatology cardiovascular and transplant dr bukofzer began his pharmaceutical career at abbott laboratories where he held a variety of positions with increasing responsibility including global venture head for abbott’s antiinfective development programs he last served as divisional vice president and head of global medical affairs where he was responsible for abbott’s global health economics and outcomes research european clinical operations and oversight for global medical and scientific functions dr bukofzer received his medical degrees from the university of witwatersrand in south africa and was accredited in internal medicine as well as gastroenterology and hepatology his research focus was in hepatitis b mutant virus genome expression following the completion of his studies dr bukofzer served in the military and practiced in both academia and private practice he previously sat on the executive committee of the south africa gastroenterology association and is a founding member of children’s liver disease foundation in south africa michael byrnes mba chief financial officer mr byrnes has served as chief financial officer of ocera therapeutics inc since december  he joined ocera in june  as vice president finance prior to joining ocera mr byrnes served as corporate controller of maxygen inc maxy since march  from june  to march  mr byrnes worked for neurogesx inc ngsx in financial roles of increasing responsibility most recently as director of finance from december  to june  mr byrnes served as finance and accounting manager for lipid sciences inc lipd mr byrnes’ experience also includes a variety of finance and accounting roles from  to  at adac labs a philips medical systems company and bay view capital corporation mr byrnes received a bsc in finance from santa clara university and an mba from california state university hayward mark d coffin phd vice president pharmaceutical development and manufacturing dr coffin joined ocera therapeutics inc in july  prior to his employment with ocera he worked at glaxosmithkline gsk in pharmaceutical development from october  to july  while at gsk dr coffin acquired extensive experience in all phases of drug development including the support of drug discovery in candidate selection development of formulations for use in phase   and  clinical trials filing of new drug marketing applications and technical support of postapproval changes for marketed products in his last role at gsk he served as the director of process robustness and second generation drug product development us dr coffin received his phd from the college of pharmacy at the university of texas at austin and his bs in pharmacy from purdue university amy potthoff vice president clinical operations ms potthoff joined ocera therapeutics inc in march  prior to her employment with ocera she served as vice president of medical operations at hospira inc where she was responsible for delivering clinical programs globally and led clinical program management medical writing document management quality and compliance and cmo operations prior to hospira amy began her pharmaceutical career at abbott laboratories where she acquired extensive experience in all phases of drug development and held a variety of positions with increasing responsibility lastly as division vice president of development operations in this role she led multiple functions located around the world including clinical program management clinical field operations document management medical writing medical publishing safety management clinical compliance clinical services and clinical planning and resource management with a mission of delivering clinical programs globally  while at abbott amy was also led the clinical operation aspects for the successful phase  program submission and approval of abbott laboratories hiv protease inhibitor norvir® and the successful development program submission and approval of hiv protease inhibitor kaletra®  amy holds a bachelor’s degree in microbiology from the university of illinois board of directors eckard weber md chairman of the board eckard weber md has served as the chairman of ocera’s board of directors since the closing of the merger in july  dr weber was a cofounder of private ocera and served as chief executive officer from february  to august  a member of its board of directors from its inception in december  to july  and as the chairman of private ocera’s board of directors from  to july  dr weber is also a partner with domain associates llc a private venture capital management firm focused on life sciences a position he has held since  dr weber is chairman of the board of tragara pharmaceuticals inc dr weber is a member of the board of directors of adynxx inc and alyrxx inc during the last five years dr weber served on the board of atara biotherapeutics inc nasdaqatra orexigen therapeutics inc nasdaqorex and tobira therapeutics inc nasdaqtbra dr weber was chairman of peninsula pharmaceuticals inc until the company was sold to johnson  johnson in  chairman of cerexa inc until the company was sold to forest laboratories inc in january  chairman of novacardia inc until the company was sold to merck in september  chairman of calixa therapeutics until the company was sold to cubist pharmaceuticals in december  and a board member of conforma therapeutics corporation and cabrellis pharmaceuticals corporation until they were sold to biogenidec inc and pharmion corporation respectively dr weber also has over  years of drug discovery and development experience and has been a consultant to biotechnology and pharmaceutical companies until  he was a tenured professor of pharmacology at the university of california irvine dr weber is the inventor or coinventor of numerous patents and patent applications and has published over  papers in scientific periodicals dr weber holds an undergraduate degree from kolping kolleg in germany and an md dr med from the university of ulm medical school in germany he received his postdoctoral training in neuroscience at stanford university medical school linda s grais md president and chief executive officer dr grais has served as a member of the board of directors and as our president and chief executive officer since the date of the merger with tranzyme inc in july  the “merger” as a member of the board of directors of ocera therapeutics inc when it was a privately held delaware corporation “private ocera” since january  and as president and chief executive officer of private ocera since june  prior to her employment by private ocera dr grais served as a managing member at interwest partners a venture capital firm from may  until february  from july  to july  dr grais was a founder and executive vice president of sgx pharmaceuticals inc a drug discovery company focusing on new treatments for cancer prior to that she was a corporate attorney at wilson sonsini goodrich  rosati where she practiced in such areas as venture financings public offerings and strategic partnerships before practicing law dr grais worked as an assistant clinical professor of internal medicine and critical care at the university of california san francisco she currently serves on the board of directors of arca biopharma inc nasdaqabio and pra health sciences nasdaqprah dr grais received a ba from yale university magna cum laude and phi beta kappa an md from yale medical school and a jd from stanford law school willard dere md director willard dere md has served on ocera’s board of directors since october  dr dere serves as the professor of internal medicine b lue and hope s bettilyon presidential endowed chair in internal medicine for diabetes research executive director of personalized health and coprincipal investigator of the center for clinical and translational science at the university of utah health sciences center prior to rejoining academia in november  dr dere was in the biopharmaceutical industry for  years he joined amgen in  where he held multiple roles including head of global development international research and development and both corporate and international chief medical officer he led the development program for prolia and several other programs and retired from amgen in october  he began his career at eli lilly in  and held a number of different global roles in clinical pharmacology regulatory affairs and both earlystage translational and latestage clinical research while at eli lilly he led the development of evista and forteo dr dere currently serves on the board of directors of radius health inc nasdaqrdus and biomarin pharmaceutical inc nasdaqbmrn and serves on the scientific advisory board of the california institute of regenerative medicine previously dr dere served on the faculty at the university of utah for four years and is a fellow in the american college of physicians dr dere received his ba and md from the university of california davis steven p james director steven p james has served as ocera’s lead independent director since september  mr james is interim chief executive officer and serves on the board of pionyr immunotherapeutics a biopharmaceutical company developing oncology drugs mr james served as the president and founding chief executive officer of labrys biologics inc a private venturebacked startup developing a monoclonal antibody for the prevention of chronic migraine from december  until the company was acquired by teva pharmaceuticals in july  from october  to december  mr james served as president and chief executive officer of kai pharmaceuticals inc “kai” which was acquired by amgen in  prior to joining kai he held leadership positions at exelixis inc sunesis pharmaceuticals inc and isis pharmaceuticals mr james previously held business development marketing and general management positions with landec corporation california biotechnology and eli lilly  company mr james holds a ba in biology from brown university and a masters in management from the kellogg graduate school of management at northwestern university mr james also currently serves on the board of cascadian therapeutics nasdaqcasc formerly oncothyreon inc and several private biotechnology companies and is a member of the board of trustees of middlebridge school in rhode island nina kjellson director nina kjellson has served on the board of directors of ocera since the closing of the merger in july  ms kjellson served as a member of the board of directors of private ocera from june  to july  ms kjellson is a managing director at canaan partners a venture capital firm where she has been employed since september  from june  to august  she served as a principal and general partner at interwest partners a venture capital firm from june  to june  she served as an investment manager at bay city capital a life sciences merchant bank and from october  to june  as a research associate at oracle partners a healthcare‑focused hedge fund from august  to september  ms kjellson conducted health policy and survey research with the kaiser family foundation a private foundation focusing on healthcare issues she holds a ba in human biology from stanford university ms kjellson has served as a member of the previously privatelyheld eiger biopharmaceuticals inc now listed on the nasdaq nasdaqeigr a biopharmaceutical company focused on the development of novel products for the treatment of orphan diseases ms kjellson also served on the board of directors of trius therapeutics inc a biopharmaceutical company focused on the discovery development and commercialization of antibiotics for serious infections formerly listed on the nasdaq from february  until its acquisition by cubist pharmaceuticals inc in september  anne m vanlent director anne m vanlent has served on the board of directors of ocera since the closing of the merger in july  ms vanlent served as a director of tranzyme inc from march  to july  ms vanlent is currently the president of amv advisors a company which she founded in may  to provide corporate strategy and financial consulting services to emerging growth life sciences companies from may  through april  ms vanlent was the executive vice president and chief financial officer of barrier therapeutics inc a company that developed and marketed prescription dermatology products that was publiclytraded before being acquired by stiefel laboratories in august  from july  to october  she was the executive vice president—portfolio management for sarnoff corporation a multidisciplinary research and development firm from  to  she served as the senior vice president and chief financial officer of the liposome company inc a publiclytraded biopharmaceutical company ms vanlent also currently serves as lead independent director of chair of the audit committee of and a member of the nominating and corporate governance committee of aviragen therapeutics inc nasdaqavir and as a director of and chair of the audit committee of advanced genetic technologies corporation nasdaqagtc and as a director of and a member of the compliance committee and audit committees of novelion therapeutics inc nasdaqnvln novelion was recently formed from the merger of qlt inc nasdaqqlti and aegerion pharmaceuticals inc nasdaqaegr where she served as a director chair of the audit committee and member of the compliance committee within the past five years ms vanlent formerly served on the board of directors of integra life sciences holding corporation nasdaqiart and onconova therapeutics inc nasdqaontx ms vanlent received a ba degree in physics from mount holyoke college wendell wierenga phd director dr wierenga has served on ocera’s board of directors since december  dr wierenga has served on the boards of directors of eight biotech companies including onyx pharmaceuticals inc which was listed on the nasdaq until its acquisition by amgen inc in october  and currently serves on the boards of cytokinetics incorporated nasdaqcytk concert pharmaceuticals inc nasdaqcnce and apricus biosciences inc nasdaqapri dr wierenga has also been a member of the scientific advisory board of seven biotech and pharmaceutical companies most recently dr wierenga was executive vice president research and development at santarus inc “santarus” from june  until january  prior to joining santarus in june  he was executive vice president of research and development at ambit biosciences inc a biopharmaceutical company engaged in the discovery and development of small‑molecule kinase inhibitors since january  dr wierenga served as executive vice president of research and development at neurocrine biosciences inc a biopharmaceutical company developing therapeutics for neuropsychiatric neuroinflammatory and neurodegenerative diseases from  to  from  to  dr wierenga was chief executive officer of syrrx inc “syrrx” a company focused on small‑molecule drug compounds prior to joining syrrx from  to  he was senior vice president of worldwide pharmaceutical sciences technologies and development at parke‑davis a division of warner lambert co a pharmaceutical company acquired by pfizer inc in  prior to parke‑davis dr wierenga worked at upjohn co later pharmacia  upjohn inc a pharmaceutical and biotechnology company for  years in various positions most recently as executive director of discovery research pfizer acquired pharmacia  upjohn then named pharmacia corp in  dr wierenga has led or participated in the research and development of more than  investigational new drugs over  new drug applications and  marketed products including lipitor neurontin lyrica and uceris dr wierenga received a bs from hope college and a phd in chemistry from stanford university ocera therapeutics announces completion of merger with tranzyme nasdaqocrx facebook google linkedin twitter email rss jul   previous release  next release pdf add to briefcase file is in briefcase ocera therapeutics announces completion of merger with tranzyme san diego july   globe newswire  ocera therapeutics inc ocera a clinical stage biopharmaceutical company developing novel therapeutics for orphan liver diseases and tranzyme inc nasdaqtzym tranzyme today announced that following a special meeting of the shareholders of tranzyme held on july   the ocera and tranzyme merger has closed the combined company is named ocera therapeutics inc and will trade beginning july   on the nasdaq global market under the symbol ocrx the combined company the company operates under the leadership of linda s grais md president and chief executive officer and the board of directors consists of representatives from both the former ocera and tranzyme boards prior to the merger tranzyme effected a to reverse split of its outstanding common stock after giving effect to the merger and the reverse stock split the holder of each share of the common stock of premerger ocera received approximately  shares of the companys common stock all options and warrants of premerger ocera that were outstanding prior to the merger were assumed by tranzyme in the merger immediately following the closing of the merger certain of the ocera investors including domain associates thomas mcnerney  partners sofinnova ventures interwest partners greenspring associates agechem cdib and wasatch advisors invested approximately  million in the company through a private placement financing at  per share of postsplit company stock following the merger the reverse split and the financing the company has approximately  million shares outstanding the closing of this merger represents an important milestone as ocera joins forces with tranzyme to develop ocr a differentiated product candidate for orphan liver diseases said dr grais we look forward to advancing ocr currently in phase  development to address a significant unmet need in the treatment of hepatic encephalopathy in patients with decompensated liver cirrhosis ocr has received orphan drug designation in the united states and europe and has been granted fast track status by the us food and drug administration it is estimated that there are up to one million patients with cirrhosis in the united states and approximately  hospitalizations occur annually in the united states due to complications of hepatic encephalopathy costing the healthcare system approximately  billion every year for more information about clinical trials related to ocr please visit wwwclinicaltrialsgovabout ocr ocr ornithine phenylacetate is an ammonia scavenger designed to treat hyperammonemia and associated hepatic encephalopathy in patients with liver cirrhosis acute liver failure and acute liver injury ocr through its dual mechanism of action directly lowers circulating blood levels of ammonia ammonia accumulation in the blood impairs brain cell function hepatic encephalopathy is an oftenreversible neuropsychiatric abnormality observed in patients with liver disease it is marked by a worsening of brain function when the liver is no longer able to remove toxic substances such as ammonia from the blood signs of hepatic encephalopathy include impaired cognition uncontrolled movements and decreased levels of consciousness leading to coma and death due to brain swelling ocr is being developed as an injectable formulation for hospitalized patients and as an oral formulation to treat and prevent recurrences of hepatic encephalopathy planning is underway to initiate a companysponsored phase b randomized doubleblind placebocontrolled efficacy study of ocr as an intravenous treatment for acute hepatic encephalopathy in hospitalized patients with liver cirrhosis enrollment is expected to begin in late  ocr also is the subject of two ongoing externallysponsored phase a studies in patients data from these studies are expected in about ocera therapeutics inc ocera therapeutics based in san diego california with an office in research triangle park north carolina is a clinical stage biopharmaceutical company focused on the development and commercialization of proprietary compounds to treat acute and chronic orphan liver diseases for additional information please see wwwocerainccomcautionary note regarding forwardlooking statements certain statements in this communication including the timing of enrollment initiation of our phase b clinical trial and the availability of additional data from the phase a trials of ocr constitute forwardlooking statements within the meaning of section a of the securities act and section e of the securities exchange act and are usually identified by the use of words such as anticipates believes estimates expects intends may plans projects seeks should will and variations of such words or similar expressions we intend these forwardlooking statements to be covered by the safe harbor provisions for forwardlooking statements contained in section a of the securities act and section e of the securities exchange act and are making this statement for purposes of complying with those safe harbor provisions these forwardlooking statements reflect our current views about our plans intentions expectations strategies and prospects which are based on the information currently available to us and on assumptions we have made although we believe that our plans intentions expectations strategies and prospects as reflected in or suggested by those forwardlooking statements are reasonable we can give no assurance that the plans intentions expectations or strategies will be attained or achieved furthermore actual results may differ materially from those described in the forwardlooking statements and will be affected by a variety of risks and factors that are beyond our control risks and uncertainties of the company include but are not limited to liquidity and trading market for shares following the merger and financing inability or the delay in obtaining required regulatory approvals for product candidates andor which may result in unexpected cost expenditures uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom failure to realize any value of certain product candidates developed and being developed including with respect to ocr in light of inherent risks and difficulties involved in successfully bringing product candidates to market inability to develop new product candidates and support existing products the approval by the fda and ema and any other similar foreign regulatory authorities of other competing or superior products brought to market risks resulting from unforeseen side effects risk that the market for the combined companys products may not be as large as expected inability to obtain maintain and enforce patents and other intellectual property rights or the unexpected costs associated with such enforcement or litigation inability to obtain and maintain commercial manufacturing arrangements with third party manufacturers or establish commercial scale manufacturing capabilities loss of or diminished demand from one or more key customers or distributors unexpected cost increases and pricing pressures continuing or deepening economic recession and its negative impact on customers vendors or suppliers uncertainties of cash flows and inability to meet working capital needs cost reductions that may not result in anticipated level of cost savings or cost reductions after the merger and risks associated with the possible failure to realize certain benefits of the including future financial tax accounting treatment and operating results many of these factors that will determine actual results are beyond the companys ability to control or predict other risks and uncertainties are more fully described in our annual report on form k for the year ended december   filed with the sec and in other filings that tranzyme makes and will make with the sec in connection with the proposed transactions including the definitive proxy statement filed with the sec on june   existing and prospective investors are cautioned not to place undue reliance on these forwardlooking statements which speak only as of the date hereof the statements made in this press release speak only as of the date stated herein and subsequent events and developments may cause our expectations and beliefs to change while we may elect to update these forwardlooking statements publicly at some point in the future we specifically disclaim any obligation to do so whether as a result of new information future events or otherwise except as required by law these forwardlooking statements should not be relied upon as representing our views as of any date after the date stated hereincontact inquiries susan sharpe director corporate communications ocera therapeutics inc   ssharpeocerainccom ocera  ocr novel simple hopeful unlike currently approved therapies for he ocr is unique in that it directly lowers circulating blood levels of ammonia through pathways that do not require liver function ocr ocera inlicensed ocr ornithine phenylacetate from university college london ocr is an ammonia scavenger designed to rapidly lower abnormally elevated systemic ammonia levels hyperammonemia and treat hepatic encephalopathy he in patients with liver cirrhosis and acute liver failure with severe liver impairment toxic substances that are normally removed by the liver such as ammonia accumulate in the blood elevated ammonia levels can cause swelling of the brain signs and symptoms of he include impaired cognition confusion and a decreased level of consciousness which can progress to coma and ultimately death patients are currently treated with laxatives that help eliminate ammonia in the gut and antibiotics that target ammonia production unlike currently approved therapies for he ocr is unique in that it directly lowers circulating blood levels of ammonia through pathways that do not require liver function ocr is in development as both an intravenous formulation which is well suited for the hospitalized population with acute he and as an oral formulation for potential stepdown therapy and to provide a chronic use option to maintain remission of he in patients with liver cirrhosis product formulation indication preclinical phase  phase  phase  ocr iv overt hepatic encephalopathy he oral chronic he fda orphan drug and fast track status stophe phase b trial in patients hospitalized with overt he ocera recently completed its phase b placebocontrolled randomized doubleblind trial stophe evaluating the safety tolerability pharmacokinetics and efficacy of intravenouslyadministered ocr ornithine phenylacetate in resolving neurocognitive symptoms of overt hepatic encephalopathy in hospitalized patients with elevated ammonia   the company expects to meet with the food and drug administration in the third quarter of  to discuss potential paths forward for iv ocr for more trialrelated information please see our resources page phase a trial in patients with cirrhosis for chronic he ocera recently initiated a phase a study in patients with cirrhosis to characterize the pharmacokinetics pk and pharmacodynamics pd of oral immediaterelease ocr tablets in  subjects with childpugh b cirrhosis given  different daily doses g g and g data from the phase a study is expected by the end of  for more trialrelated information please see our resources page ocera  contact ocera therapeutics inc redwood city ca  twin dolphin drive suite  redwood city ca   phone  fax click here for google map directions research triangle park nc  south miami boulevard suite  durham north carolina   phone  fax click here for google map directions inquiries please submit through contact form below  required field   your name    your email address    subject  general questioninvestor question   category    message  corporate whistleblower hotline report online reportonlinewebcomocera call tollfree   hours a day  days a week anytime from any location you do not have to give your name ocera  company focused on rare diseases and their ripple effects ocr has been granted orphan drug designation and fast track status by the fda for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acuteonchronic liver disease overview ocera therapeutics nasdaqocrx is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for orphan and other serious growing liver diseases with high unmet medical need ocera’s lead drug prorgam is ocr a novel and validated ammonia scavenger which rapidly removes ammonia from the blood elevated ammonia is believed to be one of the primary causes of hepatic encephalopathy he a neurocognitive disorder associated with serious liver disease an intravenouslyadministered form of ocr was the subject of a recently completed phase b trial stophe in patients hospitalized with he and an oral form of the study drug is being evaluated in an ongoing phase a trial in patients with cirrhosis ocr has received orphan drug designation and has been granted fast track status by the us food and drug administration see ocr for additional information products to treat acute and chronic orphan and other serious growing liver diseases ocera’s drug candidate ocr ornithine phenylacetate is a validated ammonia scavenger designed to treat hyperammonemia elevated ammonia in the blood and associated hepatic encephalopathy a complication of patients with liver cirrhosis or acute liver failure when the liver is no longer able to remove toxic substances from the blood there is an accumulation of such toxins particularly ammonia ammonia accumulation in the blood impairs brain cell function and can lead to a neuropsychiatric condition called hepatic encephalopathy or he management team linda s grais md president and chief executive officer dr grais has served as a member of the board of directors and as our president and chief executive officer since the date of the merger with tranzyme inc in july  the “merger” as a member of the board of directors of ocera therapeutics inc when it was a privately held delaware corporation “private ocera” since january  and as president and chief executive officer of private ocera since june  prior to her employment by private ocera dr grais served as a managing member at interwest partners a venture capital firm from may  until february  from july  to july  dr grais was a founder and executive vice president of sgx pharmaceuticals inc a drug discovery company focusing on new treatments for cancer prior to that she was a corporate attorney at wilson sonsini goodrich  rosati where she practiced in such areas as venture financings public offerings and strategic partnerships before practicing law dr grais worked as an assistant clinical professor of internal medicine and critical care at the university of california san francisco she currently serves on the board of directors of arca biopharma inc nasdaqabio and pra health sciences nasdaqprah dr grais received a ba from yale university magna cum laude and phi beta kappa an md from yale medical school and a jd from stanford law school stan bukofzer md chief medical officer dr bukofzer joined ocera therapeutics inc in january  prior to his employment with ocera he served as chief medical officer of hospira inc where he was responsible for providing strategic and operational direction for clinical development pharmacovigilance and safety and medical affairs across hospira’s three business units prior to joining hospira dr bukofzer was vice president of astellas scientific and medical affairs where he had responsibility for seven therapeutic areas including oncology immunology hematology antiinfectives dermatology cardiovascular and transplant dr bukofzer began his pharmaceutical career at abbott laboratories where he held a variety of positions with increasing responsibility including global venture head for abbott’s antiinfective development programs he last served as divisional vice president and head of global medical affairs where he was responsible for abbott’s global health economics and outcomes research european clinical operations and oversight for global medical and scientific functions dr bukofzer received his medical degrees from the university of witwatersrand in south africa and was accredited in internal medicine as well as gastroenterology and hepatology his research focus was in hepatitis b mutant virus genome expression following the completion of his studies dr bukofzer served in the military and practiced in both academia and private practice he previously sat on the executive committee of the south africa gastroenterology association and is a founding member of children’s liver disease foundation in south africa michael byrnes mba chief financial officer mr byrnes has served as chief financial officer of ocera therapeutics inc since december  he joined ocera in june  as vice president finance prior to joining ocera mr byrnes served as corporate controller of maxygen inc maxy since march  from june  to march  mr byrnes worked for neurogesx inc ngsx in financial roles of increasing responsibility most recently as director of finance from december  to june  mr byrnes served as finance and accounting manager for lipid sciences inc lipd mr byrnes’ experience also includes a variety of finance and accounting roles from  to  at adac labs a philips medical systems company and bay view capital corporation mr byrnes received a bsc in finance from santa clara university and an mba from california state university hayward mark d coffin phd vice president pharmaceutical development and manufacturing dr coffin joined ocera therapeutics inc in july  prior to his employment with ocera he worked at glaxosmithkline gsk in pharmaceutical development from october  to july  while at gsk dr coffin acquired extensive experience in all phases of drug development including the support of drug discovery in candidate selection development of formulations for use in phase   and  clinical trials filing of new drug marketing applications and technical support of postapproval changes for marketed products in his last role at gsk he served as the director of process robustness and second generation drug product development us dr coffin received his phd from the college of pharmacy at the university of texas at austin and his bs in pharmacy from purdue university amy potthoff vice president clinical operations ms potthoff joined ocera therapeutics inc in march  prior to her employment with ocera she served as vice president of medical operations at hospira inc where she was responsible for delivering clinical programs globally and led clinical program management medical writing document management quality and compliance and cmo operations prior to hospira amy began her pharmaceutical career at abbott laboratories where she acquired extensive experience in all phases of drug development and held a variety of positions with increasing responsibility lastly as division vice president of development operations in this role she led multiple functions located around the world including clinical program management clinical field operations document management medical writing medical publishing safety management clinical compliance clinical services and clinical planning and resource management with a mission of delivering clinical programs globally  while at abbott amy was also led the clinical operation aspects for the successful phase  program submission and approval of abbott laboratories hiv protease inhibitor norvir® and the successful development program submission and approval of hiv protease inhibitor kaletra®  amy holds a bachelor’s degree in microbiology from the university of illinois board of directors eckard weber md chairman of the board eckard weber md has served as the chairman of ocera’s board of directors since the closing of the merger in july  dr weber was a cofounder of private ocera and served as chief executive officer from february  to august  a member of its board of directors from its inception in december  to july  and as the chairman of private ocera’s board of directors from  to july  dr weber is also a partner with domain associates llc a private venture capital management firm focused on life sciences a position he has held since  dr weber is chairman of the board of tragara pharmaceuticals inc dr weber is a member of the board of directors of adynxx inc and alyrxx inc during the last five years dr weber served on the board of atara biotherapeutics inc nasdaqatra orexigen therapeutics inc nasdaqorex and tobira therapeutics inc nasdaqtbra dr weber was chairman of peninsula pharmaceuticals inc until the company was sold to johnson  johnson in  chairman of cerexa inc until the company was sold to forest laboratories inc in january  chairman of novacardia inc until the company was sold to merck in september  chairman of calixa therapeutics until the company was sold to cubist pharmaceuticals in december  and a board member of conforma therapeutics corporation and cabrellis pharmaceuticals corporation until they were sold to biogenidec inc and pharmion corporation respectively dr weber also has over  years of drug discovery and development experience and has been a consultant to biotechnology and pharmaceutical companies until  he was a tenured professor of pharmacology at the university of california irvine dr weber is the inventor or coinventor of numerous patents and patent applications and has published over  papers in scientific periodicals dr weber holds an undergraduate degree from kolping kolleg in germany and an md dr med from the university of ulm medical school in germany he received his postdoctoral training in neuroscience at stanford university medical school linda s grais md president and chief executive officer dr grais has served as a member of the board of directors and as our president and chief executive officer since the date of the merger with tranzyme inc in july  the “merger” as a member of the board of directors of ocera therapeutics inc when it was a privately held delaware corporation “private ocera” since january  and as president and chief executive officer of private ocera since june  prior to her employment by private ocera dr grais served as a managing member at interwest partners a venture capital firm from may  until february  from july  to july  dr grais was a founder and executive vice president of sgx pharmaceuticals inc a drug discovery company focusing on new treatments for cancer prior to that she was a corporate attorney at wilson sonsini goodrich  rosati where she practiced in such areas as venture financings public offerings and strategic partnerships before practicing law dr grais worked as an assistant clinical professor of internal medicine and critical care at the university of california san francisco she currently serves on the board of directors of arca biopharma inc nasdaqabio and pra health sciences nasdaqprah dr grais received a ba from yale university magna cum laude and phi beta kappa an md from yale medical school and a jd from stanford law school willard dere md director willard dere md has served on ocera’s board of directors since october  dr dere serves as the professor of internal medicine b lue and hope s bettilyon presidential endowed chair in internal medicine for diabetes research executive director of personalized health and coprincipal investigator of the center for clinical and translational science at the university of utah health sciences center prior to rejoining academia in november  dr dere was in the biopharmaceutical industry for  years he joined amgen in  where he held multiple roles including head of global development international research and development and both corporate and international chief medical officer he led the development program for prolia and several other programs and retired from amgen in october  he began his career at eli lilly in  and held a number of different global roles in clinical pharmacology regulatory affairs and both earlystage translational and latestage clinical research while at eli lilly he led the development of evista and forteo dr dere currently serves on the board of directors of radius health inc nasdaqrdus and biomarin pharmaceutical inc nasdaqbmrn and serves on the scientific advisory board of the california institute of regenerative medicine previously dr dere served on the faculty at the university of utah for four years and is a fellow in the american college of physicians dr dere received his ba and md from the university of california davis steven p james director steven p james has served as ocera’s lead independent director since september  mr james is interim chief executive officer and serves on the board of pionyr immunotherapeutics a biopharmaceutical company developing oncology drugs mr james served as the president and founding chief executive officer of labrys biologics inc a private venturebacked startup developing a monoclonal antibody for the prevention of chronic migraine from december  until the company was acquired by teva pharmaceuticals in july  from october  to december  mr james served as president and chief executive officer of kai pharmaceuticals inc “kai” which was acquired by amgen in  prior to joining kai he held leadership positions at exelixis inc sunesis pharmaceuticals inc and isis pharmaceuticals mr james previously held business development marketing and general management positions with landec corporation california biotechnology and eli lilly  company mr james holds a ba in biology from brown university and a masters in management from the kellogg graduate school of management at northwestern university mr james also currently serves on the board of cascadian therapeutics nasdaqcasc formerly oncothyreon inc and several private biotechnology companies and is a member of the board of trustees of middlebridge school in rhode island nina kjellson director nina kjellson has served on the board of directors of ocera since the closing of the merger in july  ms kjellson served as a member of the board of directors of private ocera from june  to july  ms kjellson is a managing director at canaan partners a venture capital firm where she has been employed since september  from june  to august  she served as a principal and general partner at interwest partners a venture capital firm from june  to june  she served as an investment manager at bay city capital a life sciences merchant bank and from october  to june  as a research associate at oracle partners a healthcare‑focused hedge fund from august  to september  ms kjellson conducted health policy and survey research with the kaiser family foundation a private foundation focusing on healthcare issues she holds a ba in human biology from stanford university ms kjellson has served as a member of the previously privatelyheld eiger biopharmaceuticals inc now listed on the nasdaq nasdaqeigr a biopharmaceutical company focused on the development of novel products for the treatment of orphan diseases ms kjellson also served on the board of directors of trius therapeutics inc a biopharmaceutical company focused on the discovery development and commercialization of antibiotics for serious infections formerly listed on the nasdaq from february  until its acquisition by cubist pharmaceuticals inc in september  anne m vanlent director anne m vanlent has served on the board of directors of ocera since the closing of the merger in july  ms vanlent served as a director of tranzyme inc from march  to july  ms vanlent is currently the president of amv advisors a company which she founded in may  to provide corporate strategy and financial consulting services to emerging growth life sciences companies from may  through april  ms vanlent was the executive vice president and chief financial officer of barrier therapeutics inc a company that developed and marketed prescription dermatology products that was publiclytraded before being acquired by stiefel laboratories in august  from july  to october  she was the executive vice president—portfolio management for sarnoff corporation a multidisciplinary research and development firm from  to  she served as the senior vice president and chief financial officer of the liposome company inc a publiclytraded biopharmaceutical company ms vanlent also currently serves as lead independent director of chair of the audit committee of and a member of the nominating and corporate governance committee of aviragen therapeutics inc nasdaqavir and as a director of and chair of the audit committee of advanced genetic technologies corporation nasdaqagtc and as a director of and a member of the compliance committee and audit committees of novelion therapeutics inc nasdaqnvln novelion was recently formed from the merger of qlt inc nasdaqqlti and aegerion pharmaceuticals inc nasdaqaegr where she served as a director chair of the audit committee and member of the compliance committee within the past five years ms vanlent formerly served on the board of directors of integra life sciences holding corporation nasdaqiart and onconova therapeutics inc nasdqaontx ms vanlent received a ba degree in physics from mount holyoke college wendell wierenga phd director dr wierenga has served on ocera’s board of directors since december  dr wierenga has served on the boards of directors of eight biotech companies including onyx pharmaceuticals inc which was listed on the nasdaq until its acquisition by amgen inc in october  and currently serves on the boards of cytokinetics incorporated nasdaqcytk concert pharmaceuticals inc nasdaqcnce and apricus biosciences inc nasdaqapri dr wierenga has also been a member of the scientific advisory board of seven biotech and pharmaceutical companies most recently dr wierenga was executive vice president research and development at santarus inc “santarus” from june  until january  prior to joining santarus in june  he was executive vice president of research and development at ambit biosciences inc a biopharmaceutical company engaged in the discovery and development of small‑molecule kinase inhibitors since january  dr wierenga served as executive vice president of research and development at neurocrine biosciences inc a biopharmaceutical company developing therapeutics for neuropsychiatric neuroinflammatory and neurodegenerative diseases from  to  from  to  dr wierenga was chief executive officer of syrrx inc “syrrx” a company focused on small‑molecule drug compounds prior to joining syrrx from  to  he was senior vice president of worldwide pharmaceutical sciences technologies and development at parke‑davis a division of warner lambert co a pharmaceutical company acquired by pfizer inc in  prior to parke‑davis dr wierenga worked at upjohn co later pharmacia  upjohn inc a pharmaceutical and biotechnology company for  years in various positions most recently as executive director of discovery research pfizer acquired pharmacia  upjohn then named pharmacia corp in  dr wierenga has led or participated in the research and development of more than  investigational new drugs over  new drug applications and  marketed products including lipitor neurontin lyrica and uceris dr wierenga received a bs from hope college and a phd in chemistry from stanford university ocera therapeutics inc nasdaqocrx ocera therapeutics inc ocrx product news news  stocknewscom     follow us stocktwits twitter ocera therapeutics inc ocrx product news news ocrx – company has begun dosing of the first patients in part two of a phasephase a clinical trial of oral ocr jun    am  by stocknewscom staff product news key facts surrounding this news item ocrx had a powr rating of f strong sell coming into today ocrx was  below its day moving average coming into today ocrx was  below its day moving average coming into today ocrx was  below its day moving average coming into today ocrx was  below its day moving average coming into today ocrx was  below its day moving average coming into today ocrx had returned  yeartodate leading up to today’s news versus a  return from the benchmark sp  during the same period more info about ocera therapeutics inc ocrx ocera therapeutics inc operates as a clinical stage biopharmaceutical company the company is based in palo alto california view our full ocrx ticker page with ratings news and more ocrx at a glance ocrx current powr rating™ overall powr rating™ ocrx current price   more ocrx ratings data and news ocrx price reaction the day of this event jun  ocrx closing price ocrx volume from avgleading up to this eventocrx mo returnafter this eventocrx day returnocrx day returnocrx day return ocrx price chart more ocera therapeutics inc ocrx news view all eventdate symbol news detail start price end price change powr rating loading please wait view all ocrx news page generated in  seconds ocrx key statistics  ocera therapeutics inc financial ratios  marketwatch bulletin investor alert expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close ocera therapeutics inc nasdaq ocrx go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus ocera therapeutics inc market closed  quotes are delayed by  min jul    pm ocrx quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite previous close     change   day low day high    week low  week high   company description ocera therapeutics inc is a clinical stage biopharmaceutical company it engages in development and commercialization of ocr ornithine phenylacetate in intravenous and oral formulations the company was founded by wu xiaoyun john c kappes and eckard weber on january   and is headqu ocera therapeutics inc is a clinical stage biopharmaceutical company it engages in development and commercialization of ocr ornithine phenylacetate in intravenous and oral formulations the company was founded by wu xiaoyun john c kappes and eckard weber on january   and is headquartered in palo alto ca valuation pe current  pe ratio with extraordinary items  price to sales ratio  price to book ratio  enterprise value to ebitda  enterprise value to sales  total debt to enterprise value  efficiency revenueemployee  income per employee  receivables turnover  total asset turnover  liquidity current ratio  quick ratio  cash ratio  profitability operating margin  pretax margin  net margin  return on assets  return on equity  return on total capital  return on invested capital  capital structure total debt to total equity  total debt to total capital  total debt to total assets  officers and executives name age officer since title dr linda s grais   president chief executive officer  director mr michael byrnes   chief financial  principal accounting officer dr stan bukofzer   chief medical officer ms amy potthoff   vice presidentclinical operations dr mark coffin   vppharmaceutical development  manufacturing insider actions – purchase – sale  – number of transactions  date name shares transaction value  eckard weber director    award at  per share   wendell d wierenga director    award at  per share   steven p james director    award at  per share   anne m vanlent director    award at  per share   nina sofia kjellson director    award at  per share   willard h dere director    award at  per share   linda s grais president and ceo director    award at  per share   stan bukofzer chief medical officer    award at  per share   michael byrnes cfo and treasurer    award at  per share   michael byrnes cfo and treasurer    acquisition at  per share   linda s grais president and ceo director    acquisition at  per share   sofinnova ventures inc director      sofinnova ventures inc director      sofinnova ventures inc director      sofinnova ventures inc director      stan bukofzer chief medical officer    acquisition at  per share   sofinnova ventures inc director    disposition at  per share   sofinnova ventures inc director    disposition at  per share   sofinnova ventures inc director    disposition at  per share   sofinnova ventures inc director      sofinnova ventures inc director      sofinnova ventures inc director      sofinnova ventures inc director    disposition at  per share   mike f powell director    derivativenonderivative trans at  per share   linda s grais president and ceo director    acquisition at  per share  newslatestcompanyusocrx marketwatch news on ocrx three healthcare deals today are paying huge premiums  am march    philip van doorn newsnonmarketwatchcompanyusocrx other news on ocrx ocera therapeutics inc  q  results  earnings call slides  am may    seeking alpha ocera therapeutics ocrx ceo linda grais on q  results  earnings call transcript  am may    seeking alpha commentary on great point partners positions part   am may    seeking alpha q ocera therapeutics inc  pm may    edgar online  edg  q k peregrine pharmaceuticals pphmp leads  activist investor reports  am april    investorplacecom biotech forum daily digest neurocrines big win spotlight on idera pharmaceuticals  pm april    seeking alpha premarket gainers as of  am  am april    seeking alpha preclinical study shows oceras lead product candidate halts progression of liver fibrosis in nafld model shares up  after hours  pm april    seeking alpha premarket gainers as of  am  am march    seeking alpha k ocera therapeutics inc  pm march    edgar online  edg  q k ocera therapeutics major risk great upside potential  pm march    seeking alpha biotech forum daily digest tg therapeutics continues to soar buyout rumors surround global blood therapeutics  am march    seeking alpha ocera therapeutics ocrx presents at cowen and company th annual health care conference  pm march    seeking alpha further analysis of midstage data showed oceras lead product candidate lowered ammonia levels faster than standard of care in he patients shares up  premarket  am march    seeking alpha ocera up  zacks upgrades to buy with  price target  pm feb    seeking alpha oceras lead product candidate flunks midstage he study shares plummet  premarket  am jan    seeking alpha hottest manufacturing stocks now – spcb cala mtp ocrx  am dec    investorplacecom biggest movers in manufacturing stocks now – myov elgx bmra ivac  pm dec    investorplacecom ocera therapeutics ocrx catches eye stock jumps   am dec    zackscom hottest manufacturing stocks now – gale ocrx dram prqr  am dec    investorplacecom loading more headlines at a glance ocera therapeutics inc  university avenue suite  palo alto california  phone   industry pharmaceuticals sector health carelife sciences fiscal yearend  view sec filings revenue  net income m  sales growth  employees  annual report for ocrx newspressreleasecompanyusocrx press releases on ocrx biotech stock performance review  newlink genetics ocera therapeutics ocular therapeutix and omeros  am july    pr newswire  prf ocera initiates phase a study with oral ocr in patients with cirrhosis  am june    globenewswire ocera therapeutics to host kol conference call on hepatic encephalopathy and other complications of liver disease on friday june   am may    globenewswire biotech stocks under scanner  bioverativ zosano pharma mannkind and ocera therapeutics  am may    pr newswire  prf ocera therapeutics reports first quarter  financial results and provides clinical update  pm may    globenewswire investor network ocera therapeutics inc to host earnings call  pm may    accesswire ocera therapeutics to report first quarter  financial results and provide clinical update on may    pm may    globenewswire todays research reports on biotech stocks to watch ocera therapeutics and verastem  am april    accesswire ocera therapeutics announces presentation of data showing ocr prevented progression of fibrosis in preclinical model of nonalcoholic fatty liver disease nafld  pm april    globenewswire biotech stocks on investors radar  portola pharma ovascience ocera therapeutics and ocular therapeutix  am march    pr newswire  prf ocera to present at the th annual needham healthcare conference  pm march    globenewswire ocera therapeutics inc yet another step towards putting a new drug treatment for chronic orphan liver diseases  am march    accesswire ocera therapeutics reports fourth quarter and full year  financial results and provides corporate update  am march    globenewswire biotech and pharmaceutical stocks fall on pricing concerns todays research reports on ocera therapeutics and array biopharma  am march    accesswire ocera to announce additional encouraging results from its phase b stophe study of iv ocr in patients with hepatic encephalopathy  am march    globenewswire ocera to present at the cowen and company th annual healthcare conference  pm feb    globenewswire lifshitz  miller llp announces investigation of centrue financial corporation motorola solutions inc natus medical incorporated northern dynasty minerals ltd ocera therapeutics inc psychemedics corporation rh and stemline therapeutics inc  pm feb    pr newswire  prf shareholder alert levi  korsinsky llp announces the commencement of an investigation involving possible securities fraud violations by the board of directors of ocera therapeutics inc  pm feb    businesswire  bzx ocera announces topline results for phase b study in hepatic encephalopathy  am jan    globenewswire ocera announces successful phase  clinical study of orallyadministered ocr in patients with cirrhosis  am jan    globenewswire loading more headlines trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  pm edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pcharges dropped after ‘london whale’ accused jamie dimon of making him a fall guy pgoodbye sean spicer memorable moments from the podium phow to fix wall street and bankers pay pamazon whole foods look to head off lengthy deal review phawaii adopts emergency plan for north korea missile attack p california wildfire destroys homes near yosemite pspicer quits as scaramucci accepts white house job pwhy you shouldn’t order ice on a flight and other ‘dirty little secrets’ pif you’re reading this you have a  chance of being rich p unfortunate reasons why millennials can’t have nice things or save any money pthis is the deadliest time of your life to put on weight pif like sean spicer you suddenly walk out — what should you do next pa history of sears through highs and lows pare you a money bully phow realestate tv shows determine what home buyers look for and what to do if you decide to quit your job like sean spicer pbreakingwall streets fear gaugethe vixjust logged its secondlowest close in history pwhy it might be time to invest in the companies amazon is destroying pthis is what should really worry you about stocks pbeware of the curse of the number  in the stock market psp  nasdaq post weekly gains as stock market finishes session lower loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  ocrxnasdaq gm stock quote  ocera therapeutics inc  bloomberg markets error could not add to watchlist x  watchlist ocera therapeutics inc ocrxus nasdaq gm usd   as of  pm edt  open  day range    volume  previous close  wk range     yr return  before its here its on the bloomberg terminal learn more open  day range    volume  previous close  wk range     yr return  ytd return  current pe ratio ttm  earnings per share usd ttm  market cap m usd  shares outstanding m  pricesales ttm  dividend indicated gross yield  sector health care  price change  industry pharmaceuticals biotechnology  life sciences  price change  related videos there are currently no related videos for this ticker please check back later company news press releases there are currently no news stories for this ticker please check back later  hepatic encephalopathy pipeline companies drug profiles gr kls and ornithine phenylacetate report available on  ocera initiates phase a study with oral ocr in patients with cirrhosis  ocera therapeutics to host kol conference call on hepatic encephalopathy and other complications of liver disease on friday ju  ocera therapeutics reports first quarter  financial results and provides clinical update  ocera therapeutics to report first quarter  financial results and provide clinical update on may    ocera therapeutics announces presentation of data showing ocr prevented progression of fibrosis in preclinical model of non  ocera to present at the th annual needham healthcare conference  ocera therapeutics reports fourth quarter and full year  financial results and provides corporate update  ocera to announce additional encouraging results from its phase b stophe study of iv ocr in patients with hepatic encepha  ocera to present at the cowen and company th annual healthcare conference there are currently no press releases for this ticker please check back later profile ocera therapeutics inc develops novel therapeutics products the companys products are designed to treat liver and gastrointestinal diseases address  university avesuite palo alto ca united states phone  website wwwocerainccom executives board members linda s grais presidentceosecretary michael byrnes cfotreasurer stan bukofzer chief medical officer mark coffin vppharmaceutical development amy potthoff vpclinical operations show more ocrx stock price  ocera therapeutics inc stock quote us nasdaq  marketwatch sections watchlist signup • login search bulletin us europe asia fx rates futures range d d m m m y y dow    sp     nasdaq    globaldow    gold    oil    sp  movers ctas  cof  etfc  syf  hp  isrg  hban  chk  latest newsall times eastern p charges dropped after ‘london whale’ accused jamie dimon of making him a fall guy p goodbye sean spicer memorable moments from the podium p how to fix wall street and bankers pay p amazon whole foods look to head off lengthy deal review p hawaii adopts emergency plan for north korea missile attack p california wildfire destroys homes near yosemite p spicer quits as scaramucci accepts white house job p updated why you shouldn’t order ice on a flight and other ‘dirty little secrets’ p updated if you’re reading this you have a  chance of being rich p updated  unfortunate reasons why millennials can’t have nice things or save any money to be replaced home investing quotes stocks united states ocrx overview compare quotes stock screener earnings calendar sectors nasdaq ocrx us nasdaq join td ameritrade find a broker ocera therapeutics inc watchlist createocrxalert closed last updated jul    pm edt delayed quote     previous close  advanced charting d d m m m ytd y y all   vol advanced charting  vs avg volume k  day avg  k open  close   day lowhigh  day range   week lowhigh  your watchlist customize marketwatch have watchlists log in to see them here or sign up to get started create account … or log in symbol last chg chg  no items in watchlist there are currently no items in this watchlist add ticker to watchlist go to your watchlist no saved watchlists create a list of the investments you want to track create watchlist …or try this starter list uh oh something went wrong while loading watchlist go to watchlist recently viewed tickers no recent tickers visit a quote page and your recently viewed tickers will be displayed here search tickers overview profile news charts financials historical quotes analyst estimates options sec filings insiders key data open  day range     week range    market cap m shares outstanding m public float m beta  rev per employee k pe ratio na eps  yield na dividend na exdividend date na short interest m   of float shorted  average volume k performance  day   month   month  ytd   year  recent news marketwatch other dow jones three healthcare deals today are paying huge premiums mar   at  am et by philip van doorn no headlines available recent news other news press releases ocera therapeutics inc ocrx announces dosing of first patients in phase a study in patients with cirrhosis ocera therapeutics inc nasdaqocrx announced the dosing of the first patients in part two of  jun   at  am et on smarteranalyst ocera therapeutics ocrx ceo linda grais on q  results  earnings call transcript ocera therapeutics ocrx ceo linda grais on q  results  earnings call transcript may   at  am et on seeking alpha ocera therapeutics inc  q  results  earnings call slides ocera therapeutics inc  q  results  earnings call slides may   at  am et on seeking alpha commentary on great point partners positions part  commentary on great point partners positions part  may   at  am et on seeking alpha ocera therapeutics inc ocrx announces q results shares pop ocera therapeutics inc nasdaqocrx reported financial results for the quarter ended march   and  may   at  pm et on smarteranalyst q ocera therapeutics inc q ocera therapeutics inc may   at  pm et on edgar online  edg  q k peregrine pharmaceuticals pphmp leads  activist investor reports apr   at  am et on investorplacecom biotech forum daily digest neurocrines big win spotlight on idera pharmaceuticals apr   at  pm et on seeking alpha premarket gainers as of  am apr   at  am et on seeking alpha preclinical study shows oceras lead product candidate halts progression of liver fibrosis in nafld model shares up  after hours apr   at  pm et on seeking alpha premarket gainers as of  am mar   at  am et on seeking alpha k ocera therapeutics inc mar   at  pm et on edgar online  edg  q k ocera therapeutics major risk great upside potential mar   at  pm et on seeking alpha biotech forum daily digest tg therapeutics continues to soar buyout rumors surround global blood therapeutics mar   at  am et on seeking alpha ocera therapeutics ocrx presents at cowen and company th annual health care conference mar   at  pm et on seeking alpha further analysis of midstage data showed oceras lead product candidate lowered ammonia levels faster than standard of care in he patients shares up  premarket mar   at  am et on seeking alpha ocera up  zacks upgrades to buy with  price target feb   at  pm et on seeking alpha oceras lead product candidate flunks midstage he study shares plummet  premarket jan   at  am et on seeking alpha hottest manufacturing stocks now – spcb cala mtp ocrx dec   at  am et on investorplacecom biggest movers in manufacturing stocks now – myov elgx bmra ivac dec   at  pm et on investorplacecom biotech stock performance review  newlink genetics ocera therapeutics ocular therapeutix and omeros biotech stock performance review  newlink genetics ocera therapeutics ocular therapeutix and omeros jul   at  am et on pr newswire  prf ocera initiates phase a study with oral ocr in patients with cirrhosis ocera initiates phase a study with oral ocr in patients with cirrhosis jun   at  am et on globenewswire ocera therapeutics to host kol conference call on hepatic encephalopathy and other complications of liver disease on friday june  ocera therapeutics to host kol conference call on hepatic encephalopathy and other complications of liver disease on friday june  may   at  am et on globenewswire biotech stocks under scanner  bioverativ zosano pharma mannkind and ocera therapeutics biotech stocks under scanner  bioverativ zosano pharma mannkind and ocera therapeutics may   at  am et on pr newswire  prf ocera therapeutics reports first quarter  financial results and provides clinical update ocera therapeutics reports first quarter  financial results and provides clinical update may   at  pm et on globenewswire investor network ocera therapeutics inc to host earnings call investor network ocera therapeutics inc to host earnings call may   at  pm et on accesswire ocera therapeutics to report first quarter  financial results and provide clinical update on may   ocera therapeutics to report first quarter  financial results and provide clinical update on may   may   at  pm et on globenewswire todays research reports on biotech stocks to watch ocera therapeutics and verastem apr   at  am et on accesswire ocera therapeutics announces presentation of data showing ocr prevented progression of fibrosis in preclinical model of nonalcoholic fatty liver disease nafld apr   at  pm et on globenewswire biotech stocks on investors radar  portola pharma ovascience ocera therapeutics and ocular therapeutix mar   at  am et on pr newswire  prf ocera to present at the th annual needham healthcare conference mar   at  pm et on globenewswire ocera therapeutics inc yet another step towards putting a new drug treatment for chronic orphan liver diseases mar   at  am et on accesswire ocera therapeutics reports fourth quarter and full year  financial results and provides corporate update mar   at  am et on globenewswire biotech and pharmaceutical stocks fall on pricing concerns todays research reports on ocera therapeutics and array biopharma mar   at  am et on accesswire ocera to announce additional encouraging results from its phase b stophe study of iv ocr in patients with hepatic encephalopathy mar   at  am et on globenewswire ocera to present at the cowen and company th annual healthcare conference feb   at  pm et on globenewswire lifshitz  miller llp announces investigation of centrue financial corporation motorola solutions inc natus medical incorporated northern dynasty minerals ltd ocera therapeutics inc psychemedics corporation rh and stemline therapeutics inc feb   at  pm et on pr newswire  prf shareholder alert levi  korsinsky llp announces the commencement of an investigation involving possible securities fraud violations by the board of directors of ocera therapeutics inc feb   at  pm et on businesswire  bzx ocera announces topline results for phase b study in hepatic encephalopathy jan   at  am et on globenewswire ocera announces successful phase  clinical study of orallyadministered ocr in patients with cirrhosis jan   at  am et on globenewswire ocera therapeutics inc ocera therapeutics inc is a clinical stage biopharmaceutical company it engages in development and commercialization of ocr ornithine phenylacetate in intravenous and oral formulations the company was founded by wu xiaoyun john c kappes and eckard weber on january   and is headquartered in palo alto ca see full profile analyst ratings sell under hold over buy number of ratings  full ratings  biggest price target changes for tuesday jan   at  am et on benzingacom benzingas top upgrades downgrades for january   jan   at  am et on benzingacom benzingas top initiations nov   at  am et on benzingacom competitors name chg  market cap sciclone pharmaceuticals inc  m vertex pharmaceuticals inc  b intercept pharmaceuticals inc  b enanta pharmaceuticals inc  m evoke pharma inc  m competitor data provided by partner content trending tickers powered by shop  cmg  vxx  bzun  bidu  advanced search stocks columns authors topics no results found video center learn morestoryful a division of news corp which owns marketwatch is a leading social media services company headquartered in dublin ireland storyful combines world class journalism with industryleading technology to discover verify and acquire original content and provide the ontheground sources news and media organizations need to tell the stories that matter to their audience stocks index  markets index bulletin investor alert stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies browse stocks stocks az abcdefghijklmnopqrstuvwxyzother browse by location argentina australia austria bahamas bahrain belgium bermuda botswana brazil british virgin islands canada cayman islands chile china colombia curacao cyprus czech republic denmark egypt estonia finland france germany gibraltar greece hong kong hungary iceland india indonesia ireland isle of man israel italy japan jordan kazakhstan kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia malta mauritius mexico monaco money rates morocco namibia netherlands new zealand norway oman pakistan panama peru philippines poland portugal qatar romania russia saudi arabia singapore slovakia slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand tunisia turkey ukraine united arab emirates united states venezuela western samoa log in  pm edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pcharges dropped after ‘london whale’ accused jamie dimon of making him a fall guy pgoodbye sean spicer memorable moments from the podium phow to fix wall street and bankers pay pamazon whole foods look to head off lengthy deal review phawaii adopts emergency plan for north korea missile attack p california wildfire destroys homes near yosemite pspicer quits as scaramucci accepts white house job pwhy you shouldn’t order ice on a flight and other ‘dirty little secrets’ pif you’re reading this you have a  chance of being rich p unfortunate reasons why millennials can’t have nice things or save any money pthis is the deadliest time of your life to put on weight pif like sean spicer you suddenly walk out — what should you do next pa history of sears through highs and lows pare you a money bully phow realestate tv shows determine what home buyers look for and what to do if you decide to quit your job like sean spicer pbreakingwall streets fear gaugethe vixjust logged its secondlowest close in history pwhy it might be time to invest in the companies amazon is destroying pthis is what should really worry you about stocks pbeware of the curse of the number  in the stock market psp  nasdaq post weekly gains as stock market finishes session lower loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  stocks index  markets index bulletin investor alert stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies browse stocks stocks az abcdefghijklmnopqrstuvwxyzother browse by location argentina australia austria bahamas bahrain belgium bermuda botswana brazil british virgin islands canada cayman islands chile china colombia curacao cyprus czech republic denmark egypt estonia finland france germany gibraltar greece hong kong hungary iceland india indonesia ireland isle of man israel italy japan jordan kazakhstan kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia malta mauritius mexico monaco money rates morocco namibia netherlands new zealand norway oman pakistan panama peru philippines poland portugal qatar romania russia saudi arabia singapore slovakia slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand tunisia turkey ukraine united arab emirates united states venezuela western samoa log in  pm edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pcharges dropped after ‘london whale’ accused jamie dimon of making him a fall guy pgoodbye sean spicer memorable moments from the podium phow to fix wall street and bankers pay pamazon whole foods look to head off lengthy deal review phawaii adopts emergency plan for north korea missile attack p california wildfire destroys homes near yosemite pspicer quits as scaramucci accepts white house job pwhy you shouldn’t order ice on a flight and other ‘dirty little secrets’ pif you’re reading this you have a  chance of being rich p unfortunate reasons why millennials can’t have nice things or save any money pthis is the deadliest time of your life to put on weight pif like sean spicer you suddenly walk out — what should you do next pa history of sears through highs and lows pare you a money bully phow realestate tv shows determine what home buyers look for and what to do if you decide to quit your job like sean spicer pbreakingwall streets fear gaugethe vixjust logged its secondlowest close in history pwhy it might be time to invest in the companies amazon is destroying pthis is what should really worry you about stocks pbeware of the curse of the number  in the stock market psp  nasdaq post weekly gains as stock market finishes session lower loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  stockscountryunited states index  markets index bulletin investor alert stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies location united states name exchange sector  communique laboratory inc ocqlf ootc software  property insurance holdings inc pih xnas nonlife insurance flowerscom inc cl a flws xnas specialty retail pm industries inc opmz ootc food products st capital bank ca fisb ootc banking st constitution bancorp fccy xnas banking st nrg corp fnrc ootc oil extraction st source corp srce xnas banking  motors inc etfm ootc automobiles st century fox inc cl a foxa xnas broadcasting st century fox inc cl b fox xnas broadcasting vianet group inc adr vnet xnas internetonline nd century group inc xxii xase biotechnology  kid doc inc tvmd ootc healthcare provision u inc twou xnas software xleveraged long etracs linked to wells fargo business development co index  bdcl arcx major international banks xleveraged long etracs wells fargo business development lbdc arcx major international banks d eye solutions inc tdey ootc motion picturesound recording d pioneer systems inc dpsm ootc software d systems corp ddd xnys computersconsumer electronics dicon corp tdcp ootc software dshoppingcom thds ootc mixed retailing dx industries inc dddx ootc computersconsumer electronics i group plc adr tgopy ootc finance companies m co mmm xnys diversified holding companies pea international inc tpnl xotc accounting power energy group inc pspw ootc renewable energy generation tl technologies corp ttmzf ootc advertisingmarketingpublic relations  property management inc ftpm ootc real estate agentsbrokers cable tv international inc catv ootc diversified business services licensing corp fourq ootc diversified business services com ltd adr wbai xnys gambling industries job inc adr jobs xnas employmenttraining services com inc adr wuba xnys consumer services barz international inc barz ootc networking n plus inc fplsf ootc commodity chemicals d global technologies inc sixd ootc computer services  renewable energy corp rnwr ootc multiutilities  energy ltd adr tngry ootc oil extraction  holdings plc eihdf ootc gambling industries point energy partners lp cafd xnas renewable energy generation x inc eght xnas wired telecommunications services a clean slate inc drwn ootc diversified business services aw revenue royalties income fund awrrf ootc restaurants a h belo corp series a ahc xnys publishing a schulman inc shlm xnas commodity chemicals a schulman inc  pfd slmnp ootc commodity chemicals ad makepeace co make ootc farming am castle  co cas xnys wholesalers ao smith corp aos xnys building materialsproducts ap moellermaersk as adr amkby ootc water transportshipping ap moellermaersk as series a amkaf ootc water transportshipping ap moellermaersk as series b amkbf ootc water transportshipping as roma spa asraf ootc recreational services a group inc awon ootc tobacco a networks inc aten xnys computer services a milk co ltd acopf ootc biotechnology aac holdings inc aac xnys healthcare provision aac technologies holdings inc aacaf ootc industrial electronics aac technologies holdings inc adr aacay ootc industrial electronics aaon inc aaon xnas building materialsproducts aap inc aapj ootc food products aar corp air xnys aerospace productsparts aarons inc aan xnys consumer services ab science sa abscf ootc pharmaceuticals ab svensk exportkredit elements linked to mlcx biofuels index total return fue arcx finance companies ab svensk exportkredit elements linked to mlcx grain index total return gru arcx finance companies abt financial corp abto ootc banking abacus mining  exploration corp abcff ootc general mining abakan inc abki ootc industrial products abattis bioceuticals corp attbf ootc biotechnology abaxis inc abax xnas medical equipmentsupplies abb ltd ablzf ootc industrial machinery abb ltd adr abb xnys industrial machinery abbott laboratories abt xnys pharmaceuticals abbvie inc abbv xnys biotechnology abby inc abby ootc oil extraction abcam plc abczf ootc biotechnology abcam plc adr abczy ootc biotechnology abco energy inc abce ootc industrial machinery abcourt mines inc abmbf ootc general mining aben resources ltd abnaf ootc general mining abengoa sa b agoaf ootc construction abeona therapeutics inc abeo xnas biotechnology abeona therapeutics inc wt abeow xnas abercrombie  fitch co anf xnys clothing retail aberdeen asiapacific income fund inc fax xase closedend funds aberdeen asiapacific income investment co ltd abakf ootc closedend funds aberdeen asset management plc abdnf ootc investment advisors aberdeen asset management plc adr abdny ootc investment advisors aberdeen australia equity fund inc iaf xase closedend funds aberdeen chile fund inc ch xase closedend funds aberdeen emerging markets smaller company opportunities fund inc abe xase closedend funds aberdeen global income fund inc fco xase closedend funds aberdeen greater china fund inc gch xnys closedend funds aberdeen indonesia fund inc if xase closedend funds aberdeen international inc aabvf ootc general mining aberdeen israel fund inc isl xase closedend funds aberdeen japan equity fund inc jeq xnys closedend funds aberdeen latin america equity fund inc laq xase closedend funds aberdeen singapore fund inc sgf xnys closedend funds abertis infraestructuras sa adr abrty ootc transportation services ability inc abil xnas precision products ability inc wt abiwf ootc abiomed inc abmd xnas medical equipmentsupplies abitibi royalties inc atbyf ootc general mining able energy inc able ootc gas utilities ablynx nv ablyf ootc biotechnology abm industries inc abm xnys diversified business services abraxas petroleum corp axas xnas oil extraction absecon bancorp ascn ootc banking absolute health  fitness inc ahfi ootc recreational services absolute software corp alswf ootc software abt holdings inc abot ootc precious metals abtech holdings inc abhd ootc industrial machinery abv consulting inc abvn ootc advertisingmarketingpublic relations ac immune sa aciu xnas biotechnology acacia communications inc acia xnas networking acacia diversified holdings inc acca ootc specialty retail acacia mining plc abglf ootc gold acacia research corp  acacia technologies actg xnas diversified business services acadia healthcare co inc achc xnas healthcare provision acadia pharmaceuticals inc acad xnas biotechnology acadia realty trust akr xnys acadian timber corp acazf ootc forestry  wood products acasti pharma inc acst xnas pharmaceuticals accelera innovations inc acnv ootc healthcare provision accelerate diagnostics inc axdx xnas biotechnology accelerize inc aclz xotc life insurance acceleron pharma inc xlrn xnas biotechnology accenture plc cl a acn xnys diversified business services access national corp ancx xnas banking access power inc accr ootc wired telecommunications services access worldwide communications inc awwc ootc advertisingmarketingpublic relations acciona sa acxif ootc construction acco brands corp acco xnys nondurable household products accor sa acrff ootc hotels accor sa adr accyy ootc hotels accordia golf co ltd acgff ootc recreational services accredited mortgage loan reit trust  perp cum pfd series a ahhap ootc mortgages accretive health inc achi ootc healthcare provision accuray inc aray xnas medical equipmentsupplies accuride corp acw xnys auto  commercial vehicle parts acelrx pharmaceuticals inc acrx xnas pharmaceuticals acer inc gdr reg s aceyy ootc computersconsumer electronics acerus pharmaceuticals corp trlpf ootc biotechnology aceto corp acet xnas specialty chemicals achaogen inc akao xnas biotechnology achillion pharmaceuticals inc achn xnas biotechnology aci worldwide inc aciw xnas software «» log in  pm edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pcharges dropped after ‘london whale’ accused jamie dimon of making him a fall guy pgoodbye sean spicer memorable moments from the podium phow to fix wall street and bankers pay pamazon whole foods look to head off lengthy deal review phawaii adopts emergency plan for north korea missile attack p california wildfire destroys homes near yosemite pspicer quits as scaramucci accepts white house job pwhy you shouldn’t order ice on a flight and other ‘dirty little secrets’ pif you’re reading this you have a  chance of being rich p unfortunate reasons why millennials can’t have nice things or save any money pthis is the deadliest time of your life to put on weight pif like sean spicer you suddenly walk out — what should you do next pa history of sears through highs and lows pare you a money bully phow realestate tv shows determine what home buyers look for and what to do if you decide to quit your job like sean spicer pbreakingwall streets fear gaugethe vixjust logged its secondlowest close in history pwhy it might be time to invest in the companies amazon is destroying pthis is what should really worry you about stocks pbeware of the curse of the number  in the stock market psp  nasdaq post weekly gains as stock market finishes session lower loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  ocrx stock price  ocera therapeutics inc stock quote us nasdaq  marketwatch sections watchlist signup • login search bulletin us europe asia fx rates futures range d d m m m y y dow    sp     nasdaq    globaldow    gold    oil    sp  movers ctas  cof  etfc  syf  hp  isrg  hban  chk  latest newsall times eastern p charges dropped after ‘london whale’ accused jamie dimon of making him a fall guy p goodbye sean spicer memorable moments from the podium p how to fix wall street and bankers pay p amazon whole foods look to head off lengthy deal review p hawaii adopts emergency plan for north korea missile attack p california wildfire destroys homes near yosemite p spicer quits as scaramucci accepts white house job p updated why you shouldn’t order ice on a flight and other ‘dirty little secrets’ p updated if you’re reading this you have a  chance of being rich p updated  unfortunate reasons why millennials can’t have nice things or save any money to be replaced home investing quotes stocks united states ocrx overview compare quotes stock screener earnings calendar sectors nasdaq ocrx us nasdaq join td ameritrade find a broker ocera therapeutics inc watchlist createocrxalert closed last updated jul    pm edt delayed quote     previous close  advanced charting d d m m m ytd y y all   vol advanced charting  vs avg volume k  day avg  k open  close   day lowhigh  day range   week lowhigh  your watchlist customize marketwatch have watchlists log in to see them here or sign up to get started create account … or log in symbol last chg chg  no items in watchlist there are currently no items in this watchlist add ticker to watchlist go to your watchlist no saved watchlists create a list of the investments you want to track create watchlist …or try this starter list uh oh something went wrong while loading watchlist go to watchlist recently viewed tickers no recent tickers visit a quote page and your recently viewed tickers will be displayed here search tickers overview profile news charts financials historical quotes analyst estimates options sec filings insiders key data open  day range     week range    market cap m shares outstanding m public float m beta  rev per employee k pe ratio na eps  yield na dividend na exdividend date na short interest m   of float shorted  average volume k performance  day   month   month  ytd   year  recent news marketwatch other dow jones three healthcare deals today are paying huge premiums mar   at  am et by philip van doorn no headlines available recent news other news press releases ocera therapeutics inc ocrx announces dosing of first patients in phase a study in patients with cirrhosis ocera therapeutics inc nasdaqocrx announced the dosing of the first patients in part two of  jun   at  am et on smarteranalyst ocera therapeutics ocrx ceo linda grais on q  results  earnings call transcript ocera therapeutics ocrx ceo linda grais on q  results  earnings call transcript may   at  am et on seeking alpha ocera therapeutics inc  q  results  earnings call slides ocera therapeutics inc  q  results  earnings call slides may   at  am et on seeking alpha commentary on great point partners positions part  commentary on great point partners positions part  may   at  am et on seeking alpha ocera therapeutics inc ocrx announces q results shares pop ocera therapeutics inc nasdaqocrx reported financial results for the quarter ended march   and  may   at  pm et on smarteranalyst q ocera therapeutics inc q ocera therapeutics inc may   at  pm et on edgar online  edg  q k peregrine pharmaceuticals pphmp leads  activist investor reports apr   at  am et on investorplacecom biotech forum daily digest neurocrines big win spotlight on idera pharmaceuticals apr   at  pm et on seeking alpha premarket gainers as of  am apr   at  am et on seeking alpha preclinical study shows oceras lead product candidate halts progression of liver fibrosis in nafld model shares up  after hours apr   at  pm et on seeking alpha premarket gainers as of  am mar   at  am et on seeking alpha k ocera therapeutics inc mar   at  pm et on edgar online  edg  q k ocera therapeutics major risk great upside potential mar   at  pm et on seeking alpha biotech forum daily digest tg therapeutics continues to soar buyout rumors surround global blood therapeutics mar   at  am et on seeking alpha ocera therapeutics ocrx presents at cowen and company th annual health care conference mar   at  pm et on seeking alpha further analysis of midstage data showed oceras lead product candidate lowered ammonia levels faster than standard of care in he patients shares up  premarket mar   at  am et on seeking alpha ocera up  zacks upgrades to buy with  price target feb   at  pm et on seeking alpha oceras lead product candidate flunks midstage he study shares plummet  premarket jan   at  am et on seeking alpha hottest manufacturing stocks now – spcb cala mtp ocrx dec   at  am et on investorplacecom biggest movers in manufacturing stocks now – myov elgx bmra ivac dec   at  pm et on investorplacecom biotech stock performance review  newlink genetics ocera therapeutics ocular therapeutix and omeros biotech stock performance review  newlink genetics ocera therapeutics ocular therapeutix and omeros jul   at  am et on pr newswire  prf ocera initiates phase a study with oral ocr in patients with cirrhosis ocera initiates phase a study with oral ocr in patients with cirrhosis jun   at  am et on globenewswire ocera therapeutics to host kol conference call on hepatic encephalopathy and other complications of liver disease on friday june  ocera therapeutics to host kol conference call on hepatic encephalopathy and other complications of liver disease on friday june  may   at  am et on globenewswire biotech stocks under scanner  bioverativ zosano pharma mannkind and ocera therapeutics biotech stocks under scanner  bioverativ zosano pharma mannkind and ocera therapeutics may   at  am et on pr newswire  prf ocera therapeutics reports first quarter  financial results and provides clinical update ocera therapeutics reports first quarter  financial results and provides clinical update may   at  pm et on globenewswire investor network ocera therapeutics inc to host earnings call investor network ocera therapeutics inc to host earnings call may   at  pm et on accesswire ocera therapeutics to report first quarter  financial results and provide clinical update on may   ocera therapeutics to report first quarter  financial results and provide clinical update on may   may   at  pm et on globenewswire todays research reports on biotech stocks to watch ocera therapeutics and verastem apr   at  am et on accesswire ocera therapeutics announces presentation of data showing ocr prevented progression of fibrosis in preclinical model of nonalcoholic fatty liver disease nafld apr   at  pm et on globenewswire biotech stocks on investors radar  portola pharma ovascience ocera therapeutics and ocular therapeutix mar   at  am et on pr newswire  prf ocera to present at the th annual needham healthcare conference mar   at  pm et on globenewswire ocera therapeutics inc yet another step towards putting a new drug treatment for chronic orphan liver diseases mar   at  am et on accesswire ocera therapeutics reports fourth quarter and full year  financial results and provides corporate update mar   at  am et on globenewswire biotech and pharmaceutical stocks fall on pricing concerns todays research reports on ocera therapeutics and array biopharma mar   at  am et on accesswire ocera to announce additional encouraging results from its phase b stophe study of iv ocr in patients with hepatic encephalopathy mar   at  am et on globenewswire ocera to present at the cowen and company th annual healthcare conference feb   at  pm et on globenewswire lifshitz  miller llp announces investigation of centrue financial corporation motorola solutions inc natus medical incorporated northern dynasty minerals ltd ocera therapeutics inc psychemedics corporation rh and stemline therapeutics inc feb   at  pm et on pr newswire  prf shareholder alert levi  korsinsky llp announces the commencement of an investigation involving possible securities fraud violations by the board of directors of ocera therapeutics inc feb   at  pm et on businesswire  bzx ocera announces topline results for phase b study in hepatic encephalopathy jan   at  am et on globenewswire ocera announces successful phase  clinical study of orallyadministered ocr in patients with cirrhosis jan   at  am et on globenewswire ocera therapeutics inc ocera therapeutics inc is a clinical stage biopharmaceutical company it engages in development and commercialization of ocr ornithine phenylacetate in intravenous and oral formulations the company was founded by wu xiaoyun john c kappes and eckard weber on january   and is headquartered in palo alto ca see full profile analyst ratings sell under hold over buy number of ratings  full ratings  biggest price target changes for tuesday jan   at  am et on benzingacom benzingas top upgrades downgrades for january   jan   at  am et on benzingacom benzingas top initiations nov   at  am et on benzingacom competitors name chg  market cap sciclone pharmaceuticals inc  m vertex pharmaceuticals inc  b intercept pharmaceuticals inc  b enanta pharmaceuticals inc  m evoke pharma inc  m competitor data provided by partner content trending tickers powered by shop  cmg  vxx  bzun  bidu  advanced search stocks columns authors topics no results found video center learn morestoryful a division of news corp which owns marketwatch is a leading social media services company headquartered in dublin ireland storyful combines world class journalism with industryleading technology to discover verify and acquire original content and provide the ontheground sources news and media organizations need to tell the stories that matter to their audience access to this page has been denied please verify you are a human please click i am not a robot to continue access to this page has been denied because we believe you are using automation tools to browse the website this may happen as a result of the following javascript is disabled or blocked by an extension ad blockers for example your browser does not support cookies please make sure that javascript and cookies are enabled on your browser and that you are not blocking them from loading reference id dabdeceaccf powered by perimeterx  inc access to this page has been denied please verify you are a human please click i am not a robot to continue access to this page has been denied because we believe you are using automation tools to browse the website this may happen as a result of the following javascript is disabled or blocked by an extension ad blockers for example your browser does not support cookies please make sure that javascript and cookies are enabled on your browser and that you are not blocking them from loading reference id ddcfcecefcafa powered by perimeterx  inc access to this page has been denied please verify you are a human please click i am not a robot to continue access to this page has been denied because we believe you are using automation tools to browse the website this may happen as a result of the following javascript is disabled or blocked by an extension ad blockers for example your browser does not support cookies please make sure that javascript and cookies are enabled on your browser and that you are not blocking them from loading reference id dcbeceddf powered by perimeterx  inc access to this page has been denied please verify you are a human please click i am not a robot to continue access to this page has been denied because we believe you are using automation tools to browse the website this may happen as a result of the following javascript is disabled or blocked by an extension ad blockers for example your browser does not support cookies please make sure that javascript and cookies are enabled on your browser and that you are not blocking them from loading reference id dbeceafaabefdb powered by perimeterx  inc ocera therapeutics inc ocrxo people  reuterscom x edition united states africa américa latina عربي argentina brasil canada  deutschland españa france india italia  méxico россия united kingdom united states ocera therapeutics inc ocrxo related topics stocksstock screenermarket datahealthcarepharmaceuticals overview news key developments people charts financials analysts research pulse ocrxo on consolidated issue listed on nasdaq global market usd  jul  change  chg   prev close  open  days high  days low  volume  avg vol  wk high  wk low  summary name age since current position linda grais   president chief executive officer director michael byrnes   principal financial officer chief accounting officer vice president  finance treasurer stan bukofzer   chief medical officer steven james  lead independent director willard dere   director nina kjellson   independent director michael powell  anne vanlent   independent director eckard weber   independent director wendell wierenga   independent director » insider trading biographies name description linda grais dr linda s grais md is president chief executive officer director of ocera therapeutics inc prior to her employment by private ocera dr grais served as a managing member at interwest partners a venture capital firm from may  until february  from july  to july  dr grais was a founder and executive vice president of sgx pharmaceuticals inc a drug discovery company focusing on new treatments for cancer prior to that she was a corporate attorney at wilson sonsini goodrich  rosati where she practiced in such areas as venture financings public offerings and strategic partnerships before practicing law dr grais worked as an assistant clinical professor of internal medicine and critical care at the university of california san francisco she currently serves on the board of directors of arca biopharma inc nasdaqabio dr grais received a ba from yale university magna cum laude and phi beta kappa an md from yale medical school and a jd from stanford law school michael byrnes mr michael byrnes is principal financial officer chief accounting officer vice president  finance treasurer of the company prior to joining the company mr byrnes served as corporate controller of maxygen inc since march  from june  to march  mr byrnes worked for neurogesx inc in financial roles of increasing responsibility most recently as director of finance from december  to june  mr byrnes served as finance and accounting manager for lipid sciences inc mr byrnes experience also includes a variety of finance and accounting roles from  to  at adac labs a philips medical systems company and bay view capital corporation mr byrnes received a bsc in finance from santa clara university and an mba from california state university hayward stan bukofzer dr stan bukofzer md is chief medical officer of ocera therapeutics inc he served as chief medical officer of hospira inc “hospira” where he was responsible for providing strategic and operational direction for clinical development pharmacovigilance and safety and medical affairs across hospira’s three business units from june  through september  prior to joining hospira dr bukofzer was vice president of astellas scientific and medical affairs inc from july  to june  where he had responsibility for seven therapeutic areas including oncology immunology hematology antiinfectives dermatology cardiovascular and transplant dr bukofzer started his pharmaceutical career at abbott laboratories where he held a variety of positions with increasing responsibility including global venture head for abbotts antiinfective development programs he last served as divisional vice president and head of global medical affairs where he was responsible for abbott’s global health economics and outcomes research european clinical operations and oversight for global medical and scientific functions dr bukofzer received his medical degree from the university of witwatersrand in south africa and was accredited in internal medicine as well as gastroenterology and hepatology steven james steven p james is lead independent director of ocera therapeutics inc mr james was the president and founding chief executive officer of labrys biologics inc a private venturebacked startup developing a monoclonal antibody against neuropeptide calcitonin gene related peptide cgrp for the prevention of chronic migraine until the company was acquired by teva pharmaceuticals in july  from  to  mr james served as president and chief executive officer of kai pharmaceuticals inc when it was acquired by amgen prior to joining kai he held leadership positions at exelixis inc sunesis pharmaceuticals inc and isis pharmaceuticals mr james previously held business development marketing and general management positions with landec corporation california biotechnology and eli lilly  company he holds a bachelors degree in biology from brown university and a masters degree in management from northwestern university kellogg graduate school of management mr james also currently serves on the board of armetheon inc and is a member of the board of trustees of middlebridge school in rhode island willard dere dr willard h dere md is a director of the company dr dere serves as the professor of internal medicine b lue and hope s bettilyon presidential endowed chair in internal medicine for diabetes research executive director of personalized health and coprincipal investigator of the center for clinical and translational science at the university of utah health sciences center prior to rejoining academia in november  dr dere was in the biopharmaceutical industry for  years he joined amgen in  where he held multiple roles including head of global development international research and development and both corporate and international chief medical officer he led the development program for prolia and several other programs and retired from amgen in october  he began his career at eli lilly in  and held a number of different global roles in clinical pharmacology regulatory affairs and both earlystage translational and latestage clinical research while at eli lilly he led the development of evista and forteo since  he has been a member of the board of directors of radius health and serves on the scientific advisory board of the california institute of regenerative medicine in addition he joined the board of directors of biomarin in july  dr dere attended undergraduate and medical school at the university of california davis he trained in internal medicine at the university of utah and endocrinology metabolism at the university of california at san francisco and was on the internal medicine faculty at the university of utah for  years during which time he was recognized annually with teaching awards he has published numerous articles wrote and coedited a primary care textbook was awarded the  transformational leadership award from his alma mater and is a fellow in the american college of physicians nina kjellson ms nina kjellson is an independent directors of ocera therapeutics incsince the closing of the merger ms kjellson served as a member of the board of directors of private ocera from june  to july  ms kjellson is a managing director at interwest partners a venture capital firm where she has been employed since  from june  to june  she served as an investment manager at bay city capital a life sciences merchant bank and from october  to june  as a research associate at oracle partners a healthcarefocused hedge fund from august  to september  ms kjellson conducted health policy and survey research with the kaiser family foundation a private foundation focusing on healthcare issues she holds a ba in human biology from stanford university ms kjellson also served on the board of directors of trius therapeutics inc a biopharmaceutical company focused on the discovery development and commercialization of antibiotics for serious infections formerly listed on the nasdaq from february  until its acquisition by cubist pharmaceuticals inc in september  michael powell dr michael f powell phd is no longer independent director of ocera therapeutics inc effective june   dr powell served as a member of the board of directors of private ocera from june  to july  dr powell has been a managing general partner of sofinnova ventures a venture capital firm since  from  to  dr powell served as group leader of drug delivery at genentech inc from  to  he was the director of product development for cytel corporation a biotechnology firm he is an adjunct professor at the university of kansas dr powell is currently the board president of avac aids vaccine advocacy coalition and a past strategic advisor to oneworld health and to the iavi international aids vaccine initiative innovation fund within the past five years dr powell served on the board of directors of each of trius therapeutics inc nasdaqtsrx and orexigen therapeutics inc nasdaqorex and currently serves on the board of directors of several private companies including ascenta therapeutics labrys biologics and mirna therapeutics dr powell holds a bs in chemistry and a phd in physical chemistry from the university of toronto and completed his postdoctorate work in bioorganic chemistry at the university of california anne vanlent ms anne m vanlent is an independent director of ocera therapeutics incformerly tranzyme inc ms vanlent is currently the president of amv advisors a company which she founded in may  to provide corporate strategy and financial consulting services to emerging growth life sciences companies from may  through april  ms vanlent was the executive vice president and chief financial officer of barrier therapeutics inc a company that developed and marketed prescription dermatology products that was publiclytraded before being acquired by stiefel laboratories in august  from july  to october  she was the executive vice president—portfolio management for sarnoff corporation a multidisciplinary research and development firm from  to  she served as the senior vice president and chief financial officer of the liposome company inc a publiclytraded biopharmaceutical company ms vanlent also currently serves as a director of and chair of the audit committee of aegerion pharmaceuticals inc nasdaqaegr as a director of chair of the audit committee of and a member of the nominating and corporate governance committee of biota pharmaceuticals inc nasdaqbota and as a director of chair of the audit committee of and a member of the compensation committee of onconova therapeutics inc nasdaqontx within the past five years ms vanlent formerly served on the board of directors of each of penwest pharmaceuticals co a nasdaqlisted company from  through its sale to endo pharmaceuticals inc in the fall of  and integra life sciences holding corporation nasdaqiart ms vanlent received a ba degree in physics from mount holyoke college eckard weber mr eckard weber md is an independent director of ocera therapeutics incsince the closing of the merger mr weber was a cofounder of private ocera and served as chief executive officer from february  to august  a member of its board of directors from its inception in december  to july  and as the chairman of private oceras board of directors from  to july  dr weber is also a partner with domain associates llc a private venture capital management firm focused on life sciences a position he has held since  dr weber currently serves as chief executive officer of sonexa therapeutics a seedstage biopharmaceutical company he is chairman of the board at orexigen therapeutics inc nasdaqorex and tragara pharmaceuticals inc dr weber served as a member of the board of directors of novacea inc otcnovc dr weber was chairman of peninsula pharmaceuticals inc until the company was sold to johnson  johnson in  chairman of cerexa inc until the company was sold to forest laboratories inc in january  chairman of novacardia inc until the company was sold to merck in september  chairman of calixa therapeutics until the company was sold to cubist pharmaceuticals in december  and a board member of conforma therapeutics corporation and cabrellis pharmaceuticals corporation until they were sold to biogenidec inc and pharmion corporation respectively dr weber also has over  years of drug discovery and development experience and has been a consultant to biotechnology and pharmaceutical companies until  he was a tenured professor of pharmacology at the university of california irvine dr weber is the inventor or coinventor of numerous patents and patent applications and has published over  papers in scientific periodicals dr weber holds a bs from kolping college in germany and an md from the university of ulm medical school in germany he received his postdoctoral training in neuroscience at stanford university medical wendell wierenga dr wendell wierenga phd is an independent director of ocera therapeutics inc dr wierenga has served on the boards of directors of eight biotech companies including onyx pharmaceuticals inc which was listed on the nasdaq until its acquisition by amgen inc in october  and currently anacor pharmaceuticals inc nasdaqanac cytokinetics incorporated nasdaqcytk xenoport inc nasdaqxnpt concert pharmaceuticals inc nasdaqcnce and apricus biosciences inc nasdaqapri dr wierenga has also been a member of the scientific advisory board of seven biotech and pharmaceutical companies most recently dr wierenga was executive vice president research and development at santarus inc santarus from june  until january  prior to joining santarus in june  he was executive vice president of research and development at ambit biosciences inc dr wierenga served as executive vice president of research and development at neurocrine biosciences inc a biopharmaceutical company developing therapeutics for neuropsychiatric neuroinflammatory and neurodegenerative diseases from  to  from  to  dr wierenga was chief executive officer of syrrx inc syrrx prior to joining syrrx from  to  he was senior vice president of worldwide pharmaceutical sciences technologies and development at parkedavis a division of warner lambert co prior to parkedavis dr wierenga worked at upjohn co later pharmacia  upjohn inc a pharmaceutical and biotechnology company for  years in various positions most recently as executive director of discovery research pfizer acquired pharmacia  upjohn then named pharmacia corp in  dr wierenga has led or participated in the research and development of more than  investigational new drugs over  new drug applications and  marketed products including lipitor neurontin lyrica and uceris dr wierenga received a bs from hope college and a phd in chemistry from stanford university basic compensation name fiscal year total linda grais  michael byrnes  stan bukofzer  steven james  willard dere  nina kjellson  michael powell  anne vanlent  eckard weber  wendell wierenga  as of   dec  options compensation name options value linda grais   michael byrnes   stan bukofzer   steven james   willard dere   nina kjellson   michael powell   anne vanlent   eckard weber   wendell wierenga   insider trading name shares traded price james steven p   weber eckard   kjellson nina s   vanlent anne m   wierenga wendell   dere willard h   grais linda s   byrnes michael   bukofzer stan md   byrnes michael   grais linda s   powell michael   powell michael   powell michael   powell michael   bukofzer stan md   powell michael   powell michael   powell michael   powell michael   powell michael   powell michael   powell michael   powell michael   grais linda s   » full list on insider trading related topics stocksstock screenermarket datahealthcarepharmaceuticals tzym stock quote  ocera therapeutics inc  bloomberg markets error could not add to watchlist x  watchlist ocera therapeutics inc tzymus ticker change tzymus has changed to a new ticker symbol usd volume  before its here its on the bloomberg terminal learn more volume  current pe ratio ttm  earnings per share usd ttm  market cap usd  shares outstanding  pricesales ttm  dividend indicated gross yield  sector health care  price change  industry pharmaceuticals biotechnology  life sciences  price change  related videos there are currently no related videos for this ticker please check back later company news press releases there are currently no news stories for this ticker please check back later there are currently no press releases for this ticker please check back later profile ocera therapeutics inc develops novel therapeutics products the companys products are designed to treat liver and gastrointestinal diseases address  university avesuite palo alto ca united states phone  website wwwocerainccom executives board members linda s grais presidentceosecretary michael byrnes cfotreasurer stan bukofzer chief medical officer mark coffin vppharmaceutical development amy potthoff vpclinical operations show more ocera therapeutics inc  netdania  full quote continue to netdania sign in x visit our new mobile website next time you access netdania with your mobile device home products web applications netstation application features support downloads pricing get trial five star chartnew highlights roles purchase quotelist application features support downloads pricing get trial financechart application features support downloads pricing get trial fullquotenew chartstation application features support downloads pricing get trial news alerts application server applications xml data service application pricing get trial client api application pricing get trial server api application pricing get trial mobile applications mobile app  ios apple application mobile app  android application mobile appblackberry application feeds interbank fx feednew forex stocks charts news directory calendar support references references partners contact us contact us contact us netdania privacy policy cookie policy terms and conditions your account alert central ocera therapeutics inc   gmt   todays range    start trading now your capital is at risk isinusa figures  ocera therapeutics inc open  close  year change  year  change   week high   week low  volume  inc vol  news  ocera therapeutics inc no news available for this instrument five star chart financechart chartstation netstation image chart five star chart – build your favorite menu  studies for mobile and desktop imagechart fivestarchart financechart chartstation share on tweet top brokers global forex dow jonescfd    sp cfd    nasdaq cfd    dax cfd    nikkei cfd    shanghai se    ftse cfd    hong kongcfd    asx cfd    nifty     gold    ukoil    eurusd    usdjpy    gbpusd    audusd    usdcad    eurjpy    eurgbp    gbpjpy    usdchf    eurchf    nzdusd    usdollar index    more more open an account your capital is at risk top gainers name last   dryships inc    tearlab corpora    seanergy mariti    top ships inc    essa pharma inc    checkpoint ther    ekso bionics ho    the bonton sto    dicerna pharmac    cellectar biosc    top losers name last   pernix therapeu    pavmed inc  w    oncobiologics     omega flex inc    american superc    anavex life sci    haynes internat    checkcap ltd    dare bioscience    community healt    get netdania mobile available for demo  live trading view the supported brokers products markets contact us support references about us netdania does not guarantee the accuracy of data contained on this website nor do we guarantee that data is realtime data on this website may be provided from otc market sources and market makers and not necessarily from exchanges the provided price data is indicative and may not be appropriate for trading or decision making purposes netdania does not assume any responsibility for any losses incurred from the use of the provided data netdania does not endorse or promote any broker or financial service netdania is a pure technology provider offering its software with broker integration any user of netdania software must be an existing client of one of our supported brokers netdania showcases netdania technology for the purpose of demonstrating it towards brokers and other institutions looking to white label the technology on a software subscription contract no financial services are offered promoted or recommended netdania is compensated as a technology provider by its institutional clients including its integrated brokers it is the sole responsibility of any recipient employing or requesting an offering to comply with all applicable legislation or regulation affecting it persons or entities including approved brokers not belonging to the netdania group may advertise on the netdania and its group’s websites through links banners or otherwise we have not taken any steps to verify the accuracy quality or reliability of any products information or services provided by third parties that have links on our website we accordingly provide no warranties with regard to and disclaim responsibility for any such products information or services and exclude all liability in this regard to the fullest extent permitted by relevant laws and regulations if a user of the netdania group’s websites decides to act upon any such advertising such user does so entirely at its own risk netdania’s website may be accessed worldwide the information provided on its website is however only intended for use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations none of the offerings services referred to on this website are available to recipients residing in countries where the provision of such offerings would constitute a violation of mandatory applicable legislation or regulations it is the sole responsibility of any recipient employing or requesting an offering to comply with all applicable legislation or regulation high risk investment warning endusers of the netdania software that make use of the trading integration features as direct clients of integrated brokers should be aware of the level of risk carried by trading in financial markets trading foreign exchange and or other financial instruments on margin carries a high level of risk and may not be suitable for all investors the high degree of leverage can work against you as well as for you before deciding to invest you should carefully consider your investment objectives level of experience and risk appetite the possibility exists that you could sustain a loss of some or more of your initial investment and therefore you should not invest money that you cannot afford to lose you should be aware of all the risks associated with trading and seek advice from your broker and or an independent financial advisor if you have any doubts anyone opening a live trading account needs to adhere to the laws of their local country as such laws may differ from country to country netdania expressly disclaims any liability for any lost principal or profits which without limitation may arise directly or indirectly from the use of or reliance on information on our website or the use of our software with broker integration copyright    netdania creations aps kronprinsessegade  st floor dk copenhagen k denmark   cvrnr terms and conditions and privacy policy the netdania website uses cookies and by continuing below you consent to this you can find out more here continue microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft ocera therapeutics ocrx  stock predictions  price targets facebook autocomplete demo post a rating  month price target   home trending sign up log in ocera therapeutics inc ocrx median target price   upside positive ratings  of  analysts latest  aegis capital  buy     view all analyst ratings for ocrx » facebook autocomplete demo post a rating  month price target   home trending sign up log in analyst ranking   name measured ratings sucess rate avg return  mizuho      credit suisse      jefferies      cantor fitzgerald      bank of america merrill lynch      jmp securities      goldman sachs      raymond james      fbr capital markets      william blair     flashratings  contact us facebook autocomplete demo post a rating  month price target   trending sign up log in contact flashratings your emotional state excited confused worried upset panicked angry flashratings  about us facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings  all research for my stocks the most comprehensive equity research coverage available online never miss a single piece of research upgrade downgrade or target price change by any analyst firm on any stock equity research by professional analysts  especially their rationales more than their forecasts  contains far more interesting and important information about the actual fundamentals of the traded companies than can be gathered from conventional news reports our mission is to unlock access to valuable research on stocks for all retail investors professionals institutions take advantage of our costeffective subscriptions to have flashratingss comprehensive realtime feed delivered into your intranet and trading floor platforms institutional subscriptions websites become a content licensing partner and display flashratingss popular news feed on your website content licensing advertisers advertise with us and have flashratings readers with attractive demographics take advantage of your products advertising flashratings  principles facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings principles  flashratings mission is to provide you  the investor  with as much honest and professional research on your investments as possible  we believe its much better to get a multitude of credible opinions on an investment than to arbitrarily follow any single advisor  be it your banker a friend or a tv pundit  flashratings does not provide advice our job is to accurately and objectively report on analysts credible research and opinions the only advice flashratings will ever give you is to absorb as much fundamental research and different opinions as possible and make your own decisions  flashratings favors covering analysts with proven track records but will cover all analysts as long as their research is honest and professional sign up » ocera therapeutics inc  health   web results aol search skip over navigation search the web web images images ocrx stock predictions  flashratingscom ad · flashratingscom all current analyst ratings and price targets for ocera about us flashratings principles analyst ranking privacy therapeutics inc  shoppingnet ad · shoppingnet​therapeutics inc compare shop  save deals on integrative therapeutics inc shop appliances shop health  beauty shop electronics shop jewelry  watches hashtag stock   stocks trade in the us markets ad · wwwbuyingstocksonlinenet  stocks trade in the us markets read our investment stream search web results  search several engines  searchallcom ad · wwwsearchallcom​results search for what youre looking for with s of results at searchall searches related toocera therapeutics inc ocrx message board ocera therapeutics news ocrx stock news ocrx market watch ocrx clinical stage biopharmaceutical comp ocrx ticker ocera therapeutics message boards web results ocera  hope for patients promise for families wwwocerainccom our mission ocera therapeutics is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with  contact investors nasdaq company ocr about he ocrx stock price  ocera therapeutics inc stock quote u  wwwmarketwatchcominvestingstockocrx ocera therapeutics inc stock price stock quotes and financial overviews from marketwatch ocrx stock quote  ocera therapeutics inc common stock  wwwnasdaqcomsymbolocrx stock quote for ocera therapeutics inc common stock ocrx  get realtime last sale and extended hours stock prices company news charts and companyspecific  ocera therapeutics inc  ocrx  stock price today  zacks httpswwwzackscomampstockquoteocrx view ocera therapeutics inc ocrx investment  stock information get the latest ocera therapeutics inc ocrx detailed stock quotes stock data realtime ecn  ocrxnasdaq gm stock quote  ocera therapeutics inc  httpswwwbloombergcomquoteocrxus stock analysis for ocera therapeutics inc ocrxnasdaq gm including stock price stock chart company news key statistics fundamentals and company profile ocrx news  ocera therapeutics inc company news  press  wwwmarketwatchcominvestingstockocrxnews updated news for ocera therapeutics inc  including ocrx company news press releases and other industry  stock market news ocera therapeutics inc nasdaqocrx quotes  news  google  wwwgooglecomfinancecid get detailed financial information on ocera therapeutics inc nasdaqocrx including realtime stock quotes historical charts  financial news all for free ocera therapeutics inc  thestreetcom httpswwwthestreetcomquoteocrxhtml view detailed financial information realtime news videos quotes and analysis on ocera therapeutics inc nasdaqocrx explore commentary on ocera therapeutics inc  ocera therapeutics inc ocrxo people  reuterscom wwwreuterscomfinancestockscompanyofficerssymbolocrxo dr linda s grais md is president chief executive officer director of ocera therapeutics inc prior to her employment by private ocera dr grais served as a  ocrx stock predictions  flashratingscom ad · flashratingscom all current analyst ratings and price targets for ocera about us flashratings principles analyst ranking privacy therapeutics inc  shoppingnet ad · shoppingnet​therapeutics inc compare shop  save deals on integrative therapeutics inc shop appliances shop health  beauty shop electronics shop jewelry  watches hashtag stock   stocks trade in the us markets ad · wwwbuyingstocksonlinenet  stocks trade in the us markets read our investment stream search web results  search several engines  searchallcom ad · wwwsearchallcom​results search for what youre looking for with s of results at searchall searches related toocera therapeutics inc ocrx message board ocera therapeutics news ocrx stock news ocrx market watch ocrx clinical stage biopharmaceutical comp ocrx ticker ocera therapeutics message boards next answers cytori therapeutics cytori therapeutics inc of the united states is a pharmaceutical company based in san diego the company develops and manufactures medical devices more acorda therapeutics products products on the market zanaflex ampyra qutenza products under development cvt plumiaz discontinued may th  references external more corcept therapeutics corcept therapeutics inc is a pharmaceutical company developing products that regulate the effects of cortisol the stress hormone and deal with more search the web  aol inc all rights reservedprivacy   terms of use   preferences   contact us   powered by bing™ wowcom  part of the aol search network ocera  hope for patients promise for families hope for patients promise for families critical drug discoveries for unmet medical needs pioneering lifechanging medicines hope for patients promise for families critical drug discoveries for unmet medical needs pioneering lifechanging medicines our mission ocera therapeutics is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with serious liver diseases in areas of high unmet medical need download fact sheet about he hepatic encephalopathy he is a debilitating and progressive complication of liver cirrhosis or liver failure marked by mental changes including confusion impaired motor skills disorientation and in its more severe form stupor coma and even death see more recent news ocera initiates phase a study with oral ocr in patients with cirrhosisthursday june  ocera therapeutics to host kol conference call on hepatic encephalopathy and other complications of liver disease on friday june friday may   see more bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one